MannKind (MNKD) 10-K 25 Feb 20 2019 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2019	Feb. 13, 2020	Jun. 28, 2019
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Trading Symbol	MNKD
Entity Registrant Name	MANNKIND CORP
Entity Central Index Key	0000899460
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity File Number	000-50865
Entity Tax Identification Number	13-3607736
Entity Address, Address Line One	30930 Russell Ranch Road
Entity Address, Address Line Two	Suite 300
Entity Address, City or Town	Westlake Village
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	91362
City Area Code	(818)
Local Phone Number	661-5000
Entity Common Stock, Shares Outstanding		212,295,318
Entity Public Float			$ 194,244,712
Document Annual Report	true
Document Transition Report	false
Entity Incorporation, State or Country Code	DE
Title of 12(b) Security	Common Stock, par value $0.01 per share
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Documents Incorporated by Reference	Portions of the registrant’s definitive Proxy Statement (the “Proxy Statement”) for the 2020 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than April 29, 2020 are incorporated by reference in Part III of this Annual Report on Form 10-K.

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 29,906	$ 71,157
Restricted cash	316	527
Short-term investments	19,978
Accounts receivable, net	3,513	4,017
Inventory	4,155	3,597
Prepaid expenses and other current assets	2,889	2,556
Total current assets	60,757	81,854
Property and equipment, net	26,778	25,602
Other assets	6,190	249
Total assets	93,725	107,705
Current liabilities:
Accounts payable	4,789	5,379
Accrued expenses and other current liabilities	15,904	15,022
Facility financing obligation		11,298
Short-term note payable	5,028
Deferred revenue — current	32,503	36,885
Recognized loss on purchase commitments — current	7,394	6,657
Total current liabilities	65,618	75,241
Promissory notes	70,020	72,089
Accrued interest — promissory notes	2,002	6,835
Long-term Midcap credit facility	38,851
Senior convertible notes	5,000	19,099
Recognized loss on purchase commitments — long term	84,639	91,642
Operating lease liability	2,514
Deferred revenue — long term	8,344	10,680
Milestone rights liability	7,263	7,201
Total liabilities	284,251	282,787
Commitments and contingencies (Note 13)
Stockholders' deficit:
Undesignated preferred stock, $0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at December 31, 2019 and 2018
Common stock, $0.01 par value — 280,000,000 shares authorized, 211,787,573 and 187,029,967 shares issued and outstanding at December 31, 2019 and 2018, respectively	2,118	1,870
Additional paid-in capital	2,799,278	2,763,067
Accumulated other comprehensive loss	(19)	(19)
Accumulated deficit	(2,991,903)	(2,940,000)
Total stockholders' deficit	(190,526)	(175,082)
Total liabilities and stockholders' deficit	$ 93,725	$ 107,705

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2019	Dec. 31, 2018
Statement Of Financial Position [Abstract]
Undesignated preferred stock, par value	$ 0.01	$ 0.01
Undesignated preferred stock, shares authorized	10,000,000	10,000,000
Undesignated preferred stock, shares issued	0	0
Undesignated preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	280,000,000	280,000,000
Common stock, shares issued	211,787,573	187,029,967
Common stock, shares outstanding	211,787,573	187,029,967

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Revenues:
Total revenues	$ 63,038	$ 27,859
Expenses:
Cost of goods sold	20,078	19,392
Research and development	6,900	8,737
Selling, general and administrative	74,669	79,716
Gain on foreign currency translation	(1,913)	(4,468)
Total expenses	107,635	104,454
Loss from operations	(44,597)	(76,595)
Other (expense) income:
Interest income	997	501
Interest expense on notes	(6,304)	(5,116)
Interest expense on promissory notes	(4,602)	(4,323)
Gain (loss) on extinguishment of debt	3,529	(765)
Other expense	(926)	(437)
Total other expense	(7,306)	(10,140)
Loss before income tax expense	(51,903)	(86,735)
Provision for income taxes	0	240
Net loss	$ (51,903)	$ (86,975)
Net loss per share — basic and diluted	$ (0.27)	$ (0.60)
Shares used to compute net loss per share — basic and diluted	195,584	144,136
Commercial product sales
Revenues:
Total revenues	$ 25,304	$ 17,276
Collaborations and services
Revenues:
Total revenues	37,734	10,583
Expenses:
Cost of revenue	$ 7,901	$ 1,077

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (51,903)	$ (86,975)
Other comprehensive loss:
Cumulative translation loss		(1)
Comprehensive loss	$ (51,903)	$ (86,976)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Deficit - USD ($) $ in Thousands	Total	Public Offering	At-the-market Offering	At-The-Market-Placement	Note Payable to Related Party	Senior Convertible Notes	Facility Financing Obligation	Promissory notesMann Group	Common Stock	Common StockPublic Offering	Common StockAt-the-market Offering	Common StockAt-The-Market-Placement	Common StockNote Payable to Related Party	Common StockSenior Convertible Notes	Common StockFacility Financing Obligation	Common StockPromissory notesMann Group	Additional Paid-in Capital	Additional Paid-in CapitalPublic Offering	Additional Paid-in CapitalAt-the-market Offering	Additional Paid-in CapitalAt-The-Market-Placement	Additional Paid-in CapitalNote Payable to Related Party	Additional Paid-in CapitalSenior Convertible Notes	Additional Paid-in CapitalFacility Financing Obligation	Additional Paid-in CapitalPromissory notesMann Group	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning Balance at Dec. 31, 2017	$ (214,732)								$ 1,192								$ 2,638,992								$ (18)	$ (2,854,898)
Beginning Balance (in shares) at Dec. 31, 2017									119,053,000
Exercise of stock options	7																7
Exercise of stock options (in shares)									7,000
Issuance of common stock from the release of restricted stock units	1								$ 2								(1)
Issuance of common stock from the release of restricted stock units (in shares)									193,000
Issuance of common stock under Employee Stock Purchase Plan	345								$ 3								342
Issuance of common stock under Employee Stock Purchase Plan (in shares)									400,000
Stock-based compensation expense	6,857																6,857
Issuance of common stock pursuant to conversion notes					$ 8,160	$ 4,980	$ 38,128						$ 30	$ 27	$ 197						$ 8,130	$ 4,953	$ 37,931
Issuance of common stock pursuant to conversion notes (in shares)													3,000,000	2,726,000	19,726,000
Issuance of common stock — direct placement	28,000								$ 140								27,860
Issuance of common stock — direct placement									14,000,000
Issuance costs associated with direct placement	(1,610)																(1,610)
Issuance of common stock		$ 40,000		$ 2,089						$ 267		$ 10						$ 39,733		$ 2,079
Issuance of common stock (in shares)										26,667,000		1,028,000
Issuance cost associated with public offering	(2,538)																(2,538)
Issuance costs associated with at-the-market placement	(84)																(84)
Issuance of common stock under Market Price Stock Purchase Plan	430								$ 2								428
Issuance of common stock under Market Price Stock Purchase Plan (in shares)									230,000
Amortization of shelf fees	(12)																(12)
Cumulative translation (loss) gain	(1)																								(1)
Adjustment to adopt ASU 2014-09 (Topic 606) | Topic 606	1,873																									1,873
Net loss	(86,975)																									(86,975)
Ending Balance at Dec. 31, 2018	(175,082)								$ 1,870								2,763,067								(19)	(2,940,000)
Ending Balance (in shares) at Dec. 31, 2018									187,030,000
Exercise of stock options	$ 124								$ 1								123
Exercise of stock options (in shares)	67,461								68,000
Issuance of common stock from the release of restricted stock units	$ (2)								$ 7								(9)
Issuance of common stock from the release of restricted stock units (in shares)									705,000
Issuance of common stock under Employee Stock Purchase Plan	656								$ 7								649
Issuance of common stock under Employee Stock Purchase Plan (in shares)									653,000
Stock-based compensation expense	6,203																6,203
Issuance of common stock pursuant to conversion notes	4,575					$ 5,575		$ 8,000	$ 42					$ 49		$ 71	4,533					$ 5,526		$ 7,929
Issuance of common stock pursuant to conversion notes (in shares)									4,193,000					4,911,000		7,143,000
Issuance of common stock			$ 3,199								$ 26								$ 3,173
Issuance of common stock (in shares)											2,585,000
Issuance costs associated with at-the-market placement	(60)																(60)
Issuance of warrants pursuant to MidCap Credit Facility	1,854																1,854
Issuance of common stock from the exercise of warrants	5,900								$ 45								5,855
Issuance of common stock from the exercise of warrants (in Share)									4,500,000
Warrant modification	688																688
Repurchase of warrants	(253)																(253)
Net loss	(51,903)																									(51,903)
Ending Balance at Dec. 31, 2019	$ (190,526)								$ 2,118								$ 2,799,278								$ (19)	$ (2,991,903)
Ending Balance (in shares) at Dec. 31, 2019									211,788,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (51,903,000)	$ (86,975,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Payment-in-kind interest on promissory notes	(32,822,000)
Interest expense on promissory notes	4,712,000	4,488,000
Stock-based compensation expense	6,203,000	6,857,000
Gain on foreign currency translation	(1,913,000)	(4,468,000)
(Gain) loss on extinguishment of debt	(3,529,000)	765,000
Amortization of right-of-use assets	1,182,000
Depreciation, amortization and accretion	972,000	2,857,000
Loss on warrant transactions	868,000
Gain on sale, abandonment/disposal or impairment of property and equipment		(114,000)
Write-off of inventory	0	2,212,000
Other, net	107,000	(35,000)
Changes in operating assets and liabilities:
Accounts receivable, net	504,000	(1,339,000)
Inventory	(558,000)	(3,152,000)
Prepaid expenses and other current assets	(333,000)	454,000
Other assets	(549,000)	200,000
Accounts payable	(593,000)	(1,605,000)
Accrued expenses and other current liabilities	3,498,000	2,249,000
Deferred revenue	(6,717,000)	46,814,000
Recognized loss on purchase commitments	(4,395,000)	(6,939,000)
Operating lease liabilities	(1,672,000)
Accrued interest on Mann Group promissory notes	(1,545,000)
Net cash used in operating activities	(88,483,000)	(37,731,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of treasury bills	(44,971,000)
Proceeds from sale of treasury bills	24,993,000
Purchase of property and equipment	(2,565,000)	(354,000)
Proceeds from sale of property and equipment		120,000
Purchase of limited liability company ownership interest	(300,000)
Net cash used in investing activities	(22,843,000)	(234,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from promissory notes	70,051,000
Proceeds from MidCap Credit Facility	40,000,000
Proceeds from senior convertible notes	9,910,000
Principal payments on Mann Group promissory notes	(38,264,000)
Principal payments on senior convertible notes	(11,081,000)
Principal payments on facility financing obligation	(6,920,000)	(5,000,000)
Issuance of common stock from the exercise of warrants	5,900,000
Proceeds from public offering		40,000,000
Milestone payment	(1,643,000)
Issuance cost associated with MidCap Credit Facility	(886,000)
Issuance cost associated with Mann Group promissory notes	(33,000)
Repurchase of warrants	(433,000)
Exercise of stock options	124,000
Proceeds from direct placement		28,000,000
Proceeds from market price stock purchase plan		430,000
Issuance cost associated with direct placement		(1,610,000)
Other		7,000
Net cash provided by financing activities	69,864,000	61,294,000
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH	(41,462,000)	23,329,000
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF PERIOD	71,684,000	48,355,000
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD	30,222,000	71,684,000
SUPPLEMENTAL CASH FLOWS DISCLOSURES:
Interest paid in cash, net of amounts capitalized	1,757,000	3,759,000
Income taxes paid in cash		240,000
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Payment on promissory notes through issuance of common stock	8,000,000	8,160,000
Addition of right-of-use assets upon adoption of new lease guidance	5,192,000
Payment of facility obligation through common stock issuance	4,575,000	37,912,000
Payment of senior convertible notes through common stock issuance	4,500,000	5,000,000
Payment of interest on senior convertible notes through common stock issuance	1,075,000
Common stock issuance to settle employee stock purchase plan liability	656,000
Issuance of warrants associated with MidCap Credit Facility	1,854,000
Public Offering
CASH FLOWS FROM FINANCING ACTIVITIES:
Issuance costs		(2,538,000)
At The Market Issuance
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from public offering	3,199,000	2,089,000
Issuance costs	$ (60,000)	$ (84,000)

Description of Business

Description of Business	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Description of Business	1. Description of Business Business — MannKind Corporation and its subsidiaries (the “Company”) is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. The Company’s only approved product, Afrezza (insulin human) Inhalation Powder, is an ultra rapid-acting inhaled insulin that was approved by the U.S. Food and Drug Administration (the “FDA”) in June 2014 to improve glycemic control in adults with diabetes. Afrezza became available by prescription in United States retail pharmacies in February 2015. Currently, the Company promotes Afrezza to endocrinologists and certain high-prescribing primary care physicians in the United States through its specialty sales force. In addition, the Company’s partner in Brazil, Biomm, commenced commercialization of Afrezza in January 2020 and the Company’s partners in India and Australia are preparing for regulatory submissions and have not yet commenced commercialization in their respective territories. Basis of Presentation — The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company is not currently profitable and has rarely generated positive net cash flow from operations. In addition, the Company expects to continue to incur significant expenditures for the foreseeable future in support of its manufacturing operations, sales and marketing costs for Afrezza, and development costs for product candidates in the Company’s pipeline. As of December 31, 2019, the Company had an accumulated deficit of $3.0 billion and $120.3 million of total principal amount of outstanding borrowings, with limited capital resources of $29.9 million in cash and cash equivalents and $20.0 million in short-term investments. These financial conditions raise substantial doubt about the Company’s ability to continue as a going concern. In August 2019, the Company and MannKind LLC entered into a credit and security agreement with MidCap Financial Trust (as amended, the “MidCap Credit Facility”) to recapitalize its debt structure (the “recapitalization”) (Refer to Note 7 – Borrowings for further details). The MidCap Credit Facility provides a secured term loan facility in an aggregate principal amount of up to $75.0 million, of which $40.0 million was outstanding as of December 31, 2019 and the remaining $35.0 million will become available under the following conditions: (1) $10.0 million will be available to the Company until April 15, 2020, subject to the satisfaction of certain conditions, including achieving Afrezza net revenue of at least $30.0 million on a trailing twelve month basis, and (2) the remaining $25.0 million will be available to the Company until June 30, 2021, subject to the satisfaction of certain milestone conditions associated with Afrezza net revenue and certain milestone conditions related to the Company’s collaboration with United Therapeutics (see Note 8 – Collaborations and Licensing Arrangements). Principal payments on the MidCap Credit Facility began in September 2021. In addition, the MidCap Credit Facility contains certain covenants, one of which includes a requirement to maintain a minimum of $15.0 million of unrestricted cash and cash equivalents. This amount will increase to $20.0 million if the Company draws the aforementioned additional funding that may be made available. As part of the recapitalization, the Company converted shares of common stock, made repayments on outstanding borrowings, and used some of the proceeds from the MidCap Credit Facility proceeds to: 1) Fully repay the remaining $5.0 million due on its financing facility with Deerfield Private Design Fund II L.P. and Deerfield Private Design International I L.P. 2) Pay down the Company’s obligations under the Mann Group promissory notes, including accrued interest, by $11.0 million and restructure the remaining $70.1 million of debt into the $35.0 million note that is convertible into shares of the Company’s common stock at $2.50 per share (the “Mann Group convertible note”) and the 3) Reduce the 5.75% Convertible Senior Subordinated Exchange Notes due 2021 (the “2021 notes”) by $8.5 million and restructure the remaining $10.2 million to the $2.6 million due June 2020 (the “June 2020 note”), $2.6 million due December 2020 (the “December 2020 note”, and together with the June 2020 note, the “2020 notes”), and the $5.0 million 5.75% Convertible Senior Subordinated Exchange Notes due November 2024 (the “2024 convertible notes”) which are convertible into shares of our common stock at $3.00 per share. The Company’s capital resources may not be sufficient to continue to meet its current and anticipated obligations over the next twelve months if the Company cannot increase its operating cash inflows by growing its prescription and revenue base and/or obtain access to the remaining $35.0 million borrowings that may become available under its MidCap Credit Facility. In the event these capital resources are not sufficient, the Company may need to raise additional capital by selling equity or debt securities, entering into strategic business collaboration agreements with other companies, seeking other funding facilities or licensing arrangements, selling assets or by other means. However, the Company cannot provide assurances that additional capital will be available on acceptable terms or at all. If the Company is unable to meet its current and anticipated obligations over the next twelve months through its existing capital resources, or obtain new sources of capital when needed, the Company may have to delay, reduce the scope of its manufacturing operations, reduce or eliminate one or more of its development programs, and/or make significant changes to its operating plan. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty. Principles of Consolidation — The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. Intercompany balances and transactions have been eliminated. Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported Consolidated Balance Sheets or Statements of Operations. An adjustment has been made to the Consolidated Statements of Cash Flows for the fiscal year ended December 31, 2018 to separately identify the disclosures of non-cash investing and financing activities related to the payment of facility obligation through common stock issuance and senior convertible notes through common stock issuance. This change in classification does not affect previously reported cash flows from operating, investing or financing activities. In addition, an adjustment has been made to reclassify certain immaterial amounts of professional fees to other accrued expenses within the table of accrued expenses in Note 5 — Accrued Expenses and Other Current Liabilities as of December 31, 2018 for consistency with the current year presentation. Segment Information — Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. To date, the Company has viewed its operations and manages its business as one segment operating in the United States of America.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Financial Statement Estimates — The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies, and in developing the estimates and assumptions that are used in the preparation of the financial statements. Management must apply significant judgment in this process. The more significant estimates reflected in these accompanying consolidated financial statements include revenue recognition and gross-to-net adjustments, assessing long-lived assets for impairment, clinical trial expenses, inventory costing and recoverability, recognized loss on purchase commitment, milestone rights liability, stock-based compensation and the determination of the provision for income taxes and corresponding deferred tax assets and liabilities and the valuation allowance recorded against net deferred tax assets. Revenue Recognition — The Company adopted Accounting Standards Codification (“ASC”) Topic 606 - Revenue from Contracts with Customers (“the new revenue guidance”), on January 1, 2018. Under Topic 606, the Company recognizes revenue when its customers obtain control of promised goods or services, in an amount that reflects the consideration which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of Topic 606, the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to arrangements that meet the definition of a contract under Topic 606, including when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company has two types of contracts with customers: (i) contracts for commercial product sales with wholesale distributors and specialty pharmacies and (ii) collaboration arrangements. Revenue Recognition – Net Revenue – Commercial Product Sales – The Company sells Afrezza to a limited number of wholesale distributors and specialty pharmacies in the U.S. (collectively, its “Customers”). Wholesale distributors subsequently resell the Company’s products to retail pharmacies and certain medical centers or hospitals. Specialty pharmacies sell directly to patients. In addition to distribution agreements with Customers, the Company enters into arrangements with payors that provide for government mandated and/or privately negotiated rebates, chargebacks, and discounts with respect to the purchase of the Company’s products. The Company recognizes revenue on product sales when the Customer obtains control of the Company's product, which occurs at delivery for wholesale distributors and at shipment for specialty pharmacies. Product revenues are recorded net of applicable reserves for variable consideration, including discounts and allowances. Free Goods Program – From time to time, the Company offers programs to potential new patients that allow them to obtain free goods (prescription fills) from a pharmacy. On a net basis, it is not probable that the Company will receive the consideration from these products. Therefore, the Company excludes such amounts from both gross and net revenue. The cost of product associated with the free goods program is included in cost of goods sold. Reserves for Variable Consideration — Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. Components of variable consideration include trade discounts and allowances, product returns, provider chargebacks and discounts, government rebates, payor rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its Customers, payors, and other indirect customers relating to the Company’s sale of its products. These reserves, as detailed below, are based on the amounts earned, or to be claimed on the related sales, and result in a reduction of accounts receivable or establishment of a current liability. Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted in accordance with the expected value method in Topic 606 for relevant factors such as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reduce recognized revenue to the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the respective underlying contracts. The amount of variable consideration which is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. The Company’s analysis also contemplates application of the constraint in accordance with the guidance, under which it determined a material reversal of revenue would not occur in a future period for the estimates detailed below as of December 31, 2019 and, therefore, the transaction price was not reduced further during the year ended December 31, 2019. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company will adjust these estimates, which would affect net revenue – commercial product sales and earnings in the period such variances become known. Trade Discounts and Allowances — The Company generally provides Customers with discounts which include incentives, such as prompt pay discounts, that are explicitly stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, the Company compensates (through trade discounts and allowances) its Customers for sales order management, data, and distribution services. However, the Company has determined such services received to date are not distinct from the Company’s sale of products to the Customer and, therefore, these payments have been recorded as a reduction of revenue and as a reduction to accounts receivable, net. Product Returns —Consistent with industry practice, the Company generally offers Customers a right of return for unopened product that has been purchased from the Company for a period beginning six months prior to and ending 12 months after its expiration date, which lapses upon shipment to a patient. The Company estimates the amount of its product sales that may be returned by its Customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized, as well as reductions to accounts receivable, net. The Company currently estimates product returns using available industry data and its own sales information, including its visibility into the inventory remaining in the distribution channel. The Company’s current return reserve percentage is estimated to be in the single digits. Provider Chargebacks and Discounts — Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase the product from the Company. Customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is recorded in accrued expenses and other current liabilities. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by Customers, and the Company generally issues credits for such amounts within a few weeks of the Customer’s notification to the Company of the resale. Reserves for chargebacks consist of credits that the Company expects to issue for units that remain in the distribution channel inventories at each reporting period-end that the Company expects will be sold to qualified healthcare providers, and chargebacks that Customers have claimed, but for which the Company has not yet issued a credit. Government Rebates — The Company is subject to discount obligations under Medicare and state Medicaid programs. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other current liabilities. For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The Company’s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel inventories at the end of each reporting period. Payor Rebates — The Company contracts with certain private payor organizations, primarily insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of its products. The Company estimates these rebates and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other current liabilities. Other Incentives — Other incentives which the Company offers include voluntary patient support programs, such as the Company's co-pay assistance program, which are intended to provide financial assistance to qualified commercially-insured patients with prescription drug co-payments required by payors. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with the product that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period. The adjustments are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other current liabilities. Revenue Recognition — Revenue — Collaborations and Services — The Company enters into licensing or research agreements under which the Company licenses certain rights to its product candidates to third parties or conducting research services to third parties. The terms of these arrangements may include, but are not limited to payment to the Company of one or more of the following: up-front license fees; development, regulatory, and commercial milestone payments; payments for manufacturing commercial and clinical supply services the Company provides; and royalties on net sales of licensed products and sublicenses of the rights. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment such as determining the performance obligation in the contract and determining the stand-alone selling price for each performance obligation identified in the contract. If an arrangement has multiple performance obligations, the allocation of the transaction price is determined from observable market inputs, and the Company uses key assumptions to determine the stand-alone selling price, which may include development timelines, reimbursement rates for personnel costs, discount rates, and probabilities of technical and regulatory success. Revenue is recognized based on the measurement of progress as the performance obligation is satisfied and consideration received that does not meet the requirements to satisfy the revenue recognition criteria is recorded as deferred revenue. Current deferred revenue consists of amounts that are expected to be recognized as revenue in the next 12 months. For further information see Note 8 Collaboration and Licensing Agreements. The Company recognizes upfront license payments as revenue upon delivery of the license only if the license is determined to be a separate unit of accounting from the other undelivered performance obligations. The undelivered performance obligations typically include manufacturing or development services or research and/or steering committee services. If the license is not considered as a distinct performance obligation, then the license and other undelivered performance obligations would be evaluated to determine if such should be accounted for as a single unit of accounting. If concluded to be a single performance obligation, the transaction price for the single performance obligation is recognized as revenue over the estimated period of when the performance obligation is satisfied. Whenever the Company determines that an arrangement should be accounted for over time, the Company determines the period over which the performance obligations will be performed, and revenue will be recognized over the period the Company is expected to complete its performance obligations. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations under an arrangement. The Company’s collaboration agreements typically entitle the Company to additional payments upon the achievement of development, regulatory and sales milestones. If the achievement of a milestone is considered probable at the inception of the collaboration, the related milestone payment is included with other collaboration consideration, such as upfront fees and research funding, in the Company’s revenue calculation. If these milestones are not considered probable at the inception of the collaboration, the milestones will typically be recognized in one of two ways depending on the timing of when the milestone is achieved. If the milestone is improbable at inception and subsequently deemed probable of achievement, such will be added to the transaction price, resulting in a cumulative adjustment to revenue. If the milestone is achieved after the performance period has completed and all performance obligations have been delivered, the Company will recognize the milestone payment as revenue in its entirety in the period the milestone was achieved. The Company’s collaborative agreements, for accounting purposes, represent contracts with customers and therefore are not subject to accounting literature on collaborative agreements. The Company grants licenses to its intellectual property, supplies raw materials or finished goods and provides research and development services, all of which are outputs of the Company’s ongoing activities, in exchange for consideration. The Company does not develop assets jointly with collaboration partners, and does not share in significant risks of their development or commercialization activities. Accordingly, the Company concluded that its collaborative agreements must be accounted for pursuant to Topic 606, Revenue from Contracts with Customers. For collaboration agreements that allow collaboration partners to select additional optioned products or services, the Company evaluates whether such options contain material rights (i.e., have exercise prices that are discounted compared to what the Company would charge for a similar product or service to a new collaboration partner). The exercise price of these options includes a combination of licensing fees, event-based milestone payments and royalties. When these amounts in aggregate are not offered at a discount that exceeds discounts available to other customers, the Company concludes the option does not contain a material right, and therefore is not included in the transaction price at contract inception. Rather, the Company evaluates grants of additional licensing rights upon option exercises to determine whether such should be accounted for as separate contracts. The Company concluded there is no material right in these options. The Company follows detailed accounting guidance in measuring revenue and certain judgments affect the application of its revenue policy. For example, in connection with its existing collaboration agreements, the Company has recorded on its consolidated balance sheets short-term and long-term deferred revenue based on its best estimate of when such revenue will be recognized. Short-term deferred revenue consists of amounts that are expected to be recognized as revenue in the next 12 months. Amounts that the Company expects will not be recognized within the next 12 months are classified as long-term deferred revenue. However, this estimate is based on the Company’s current project development plan and, if the development plan should change in the future, the Company may recognize a different amount of deferred revenue over the next 12-month period. The activity related to deferred revenue and the related revenue recognized for collaborations and services is as follows (in thousands): December 31, 2019 2018 Deferred revenue: Beginning balance $ 47,565 $ 750 Upfront and milestone payments 25,000 55,000 Pass through payments 6,016 2,398 Revenue — collaborations and services (37,734 ) (10,583 ) Ending balance $ 40,847 $ 47,565 Milestone Payments — At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the customer, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as, or when, the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company will re-evaluate the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration, other revenue, and earnings in the period of adjustment. Cost of Goods Sold — Cost of goods sold includes material, labor costs and manufacturing overhead. Cost of goods sold also includes a significant component of current period manufacturing costs in excess of costs capitalized into inventory (excess capacity costs). These costs, in addition to the impact of the annual revaluation of inventory to standard costs and write-offs of inventory are recorded as expenses in the period in which they are incurred, rather than as a portion of inventory costs. All insulin inventory on hand and the full purchase commitment contract to purchase future insulin was written off as of the end of 2015. Therefore, cost of goods sold excludes the cost of insulin purchased under our Insulin Supply Agreement, except for the contract amendment fees of approximately $2.8 million and $2.0 million for the years ended December 31, 2019 and 2018, respectively (see Note 13 – Commitments and Contingencies). Cash and Cash Equivalents – The Company considers all highly liquid investments with original or remaining maturities of 90 days or less at the time of purchase, that are readily convertible into cash to be cash equivalents. As of December 31, 2019 and 2018, cash equivalents were comprised of money market accounts with maturities less than 90 days from the date of purchase. The Company records restricted cash when cash and cash equivalents are restricted as to withdrawal or usage. The Company presents amounts of restricted cash that will be available for use within 12 months of the reporting date as restricted cash in current assets. Restricted cash amounts that will not be available for use in the Company’s operations within 12 months of the reporting date are presented as restricted cash in long term assets. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported on the consolidated balance sheets that sum to amounts reported on the consolidated statement of cash flows (in thousands): December 31, 2019 2018 Cash and cash equivalents $ 29,906 $ 71,157 Restricted cash 316 527 Total cash, cash equivalents, and restricted cash $ 30,222 $ 71,684 Short-term Investments The Company’s short-term investments consist of U.S. Treasury securities stated at amortized cost which the Company intends to hold until maturity. Those with maturities less than 12 months are included in short-term investments and any investments with maturities in excess of twelve months are included in long-term investments in our consolidated balance sheets. The Company did not record any material gains or losses on these securities during the years ended December 31, 2019 and 2018. Concentration of Credit Risk — Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents and short-term investments. Cash and cash equivalents are held in high credit quality institutions. Cash equivalents consist of interest-bearing money market accounts and U.S. Treasury securities, which are regularly monitored by management. Short-term investments consist of U.S. Treasury securities with a maximum maturity of twelve months. Accounts Receivable and Allowance for Doubtful Accounts — Accounts receivable are recorded at the invoiced amount and are not interest bearing. Accounts receivable are presented net of an allowance for doubtful accounts if there are estimated losses resulting from the inability of its customers to make required payments. The Company makes ongoing assumptions relating to the collectability of its accounts receivable in its calculation of the allowance for doubtful accounts. Accounts receivable are also presented net of an allowance for product returns and trade discounts and allowances because the Company’s customers have the right of setoff for these amounts against the related accounts receivable. Accounts receivable, net consists of the following (in thousands): December 31, 2019 2018 Accounts Receivable, gross $ 6,925 $ 5,198 Wholesaler distribution fees and prompt pay discounts (1,767 ) (868 ) Reserve for returns (1,645 ) (313 ) Accounts receivable, net $ 3,513 $ 4,017 As of December 31, 2019 and December 31, 2018, the allowance for doubtful accounts was de minimis. As of December 31, 2019 and December 31, 2018, the Company had three wholesale distributors representing approximately 96% and 89% of sales, respectively. Pre-Launch Inventory — An improvement to the manufacturing process for the Company’s primary excipient FDKP was demonstrated to be viable and management expects to realize an economic benefit in the future as a result of such process improvement. Accordingly, the Company is required to assess whether to capitalize inventory costs related to such excipient prior to regulatory approval of the new supplier and the improved manufacturing process. In doing so, management must consider a number of factors in order to determine the amount of inventory to be capitalized, including the historical experience of achieving regulatory approvals for the Company’s manufacturing process, feedback from regulatory agencies on the changes being effected and the amount of inventory that is likely to be used in commercial production. The shelf life of the excipient will be determined as part of the regulatory approval process; in the interim, the Company must assess the available stability data to determine whether there is likely to be adequate shelf life to support anticipated future sales occurring beyond the expected approval date of the new raw material. If management is aware of any specific material risks or contingencies other than the normal regulatory review and approval process, or if the criteria for capitalizing inventory produced prior to regulatory approval are otherwise not met, the Company would not capitalize such inventory costs, choosing instead to recognize such costs as a research and development expense in the period incurred. Inventories — Inventories are stated at the lower of cost or net realizable value. The Company determines the cost of inventory using the first-in, first-out, or FIFO, method. The Company capitalizes inventory costs associated with the Company’s products based on management’s judgment that future economic benefits are expected to be realized; otherwise, such costs are expensed as incurred as cost of goods sold. The Company periodically analyzes its inventory levels to identify inventory that may expire or has a cost basis in excess of its estimated realizable value and writes down such inventories, as appropriate. In addition, the Company’s products are subject to strict quality control and monitoring which the Company performs throughout the manufacturing process. If certain batches or units of product no longer meet quality specifications or may become obsolete or are forecasted to become obsolete due to expiration, the Company will record a charge to write down such unmarketable inventory to its estimated net realizable value. The Company analyzes its inventory levels to identify inventory that may expire or has a cost basis in excess of its estimated realizable value. The Company performs an assessment of projected sales and evaluates the lower of cost or net realizable value and the potential excess inventory on hand at the end of each reporting period. Impairment of Long-Lived Assets — The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Assets are considered to be impaired if the carrying value may not be recoverable. If the Company believes an asset to be impaired, the impairment recognized is the amount by which the carrying value of the asset exceeds the fair value of the asset. Fair value is determined using the market, income or cost approaches as appropriate for the asset. Any write-downs are treated as permanent reductions in the carrying amount of the asset and recognized as an operating loss. The Company recorded zero asset impairments for the years ended December 31, 2019 and 2018 (see Note 4 — Property and Equipment). Recognized Loss on Purchase Commitments — The Company assesses whether losses on long term purchase commitments should be accrued. Losses that are expected to arise from firm, non-cancellable, commitments for the future purchases are recognized unless recoverable. When making the assessment, the Company also considers whether it is able to renegotiate with its vendors. The recognized loss on purchase commitments is reduced as inventory items are received. If, subsequent to an accrual, a purchase commitment is successfully renegotiated, the gain is recognized in the Company’s consolidated statement of operations. The liability balance of the recognized loss on insulin purchase commitments as of December 31, 2019 and 2018 was $92.0 million and $98.3 million, respectively. Milestone Rights Liability — On July 1, 2013, in conjunction with the execution of the Facility Agreement, the Company issued Milestone Rights to the Milestone Purchasers. The Milestone Rights provide the Milestone Purchasers certain rights to receive payments of up to $90.0 million, of which $70.0 million remain payable as of December 31, 2019, upon the occurrence of specified strategic and sales milestones, including the achievement of specified net sales figures. The Company analyzed the Milestone Rights and determined that the Milestone Agreement does not meet the definition of a freestanding derivative. Since the Company has not elected to apply the fair value option to the Milestone Agreement, the Company recorded the Milestone Rights at their estimated initial fair value and accounted for the Milestone Rights as a liability. The initial fair value estimate of the Milestone Rights was calculated using the income approach in which the cash flows associated with the specified contractual payments were adjusted for both the expected timing and the probability of achieving the milestones and discounted to present value using a selected market discount rate. The expected timing and probability of achieving the milestones was developed with consideration given to both internal data, such as progress made to date and assessment of criteria required for achievement, and external data, such as market research studies. The discount rate was selected based on an estimation of required rate of returns for similar investment opportunities using available market data. The Milestone Rights liability will be remeasured as the specified milestone events are achieved. Specifically, as each milestone event is achieved, the portion of the initially recorded Milestone Rights liability that pertains to the milestone event being achieved, will be remeasured to the amount of the specified related milestone payment. The resulting change in the balance of the Milestone Rights liability due to remeasurement will be recorded in the Company’s consolidated statements of operations as interest expense. Furthermore, the Milestone Rights liability will be reduced upon the settlement of each milestone payment. As a result, each milestone payment would be effectively allocated between a reduction of the recorded Milestone Rights liability and an expense representing a return on a portion of the Milestone Rights liability paid to the investor for the achievement of the related milestone event (see Note 7 — Borrowings). As of December 31, 2019 and 2018, the remaining liability balance was $7.3 million and $8.9 million, respectively. Fair Value of Financial Instruments —The Company applies various valuation approaches in determining the fair value of its financial assets and liabilities within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is broken down into three levels based on the source of inputs as follows: Level 1 — Quoted prices for identical instruments in active markets. Level 2 — Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observ

Inventories

Inventories	12 Months Ended
	Dec. 31, 2019
Inventory Disclosure [Abstract]
Inventories	3. Inventories Inventories consist of the following (in thousands): December 31, 2019 2018 Raw materials $ 1,751 $ 1,337 Work-in-process 1,432 1,605 Finished goods 972 655 Total inventory $ 4,155 $ 3,597 Work-in-process and finished goods as of December 31, 2019 and 2018 include conversion costs and exclude the cost of insulin. All insulin inventory on hand was written off and the projected loss on the purchase commitment contract to purchase future insulin was accrued as of the end of 2015. Raw materials inventory included $0.8 million of pre-launch inventory as of December 31, 2019, which consisted of FDKP received in November 2019 that will be used to manufacture Afrezza under an enhanced manufacturing process for FDKP. Approximately 2% of the material received in November 2019 was recognized as a research and development expense and will be used by the Company for stability studies and other tests. The Company expects to receive FDA approval of the new source of FDKP in mid-2021, after which the pre-launch raw materials inventory will be reclassified as raw materials inventory for use in the manufacturing of Afrezza. The Company did not have any pre-launch raw materials inventory as of December 31, 2018. The Company analyzed its inventory levels to identify inventory that may expire or has a cost basis in excess of its estimated realizable value. The Company also performed an assessment of projected sales and evaluated the lower of cost or net realizable value and the potential excess inventory on hand at December 31, 2019 and 2018. Inventory that was forecasted to become obsolete due to expiration is recorded in costs of goods sold in the accompanying consolidated statements of operations. During the year ended December 31, 2018, the Company recorded a write-down of inventory of approximately $2.2 million. There were no inventory write-offs for the year ended December 31, 2019.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2019
Property Plant And Equipment [Abstract]
Property and Equipment	4. Property and Equipment Property and equipment consist of the following (in thousands): Estimated Useful December 31, Life (Years) 2019 2018 Land — $ 875 $ 875 Buildings 39-40 17,389 17,389 Building improvements 5-40 37,543 34,967 Machinery and equipment 3-15 54,982 61,217 Furniture, fixtures and office equipment 5-10 3,005 2,954 Computer equipment and software 3 8,234 8,355 Construction in progress — 114 342 122,142 126,099 Less accumulated depreciation (95,364 ) (100,497 ) Total property and equipment, net $ 26,778 $ 25,602 Depreciation expense related to property and equipment for the years ended December 31, 2019 and 2018 was $1.6 million and $1.7 million, respectively. During the year ended December 31, 2019, the Company retired $6.7 million of manufacturing equipment and computer hardware as it was no longer in service. During the year ended December 31, 2018, the Company disposed of $2.1 million of furniture and fixtures, manufacturing equipment and laboratory equipment as it was no longer in service. The net book value for the disposed assets was de minimis

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	12 Months Ended
	Dec. 31, 2019
Payables And Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	5. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities are comprised of the following (in thousands): December 31, 2019 2018 Salary and related expenses $ 8,835 $ 8,110 Discounts and allowances for commercial product sales 3,162 2,656 Deferred lease liability 1,433 257 Professional fees 620 457 Accrued interest 409 492 Sales and marketing services 147 88 Other 1,298 1,319 Current portion of milestone rights liability — 1,643 Accrued expenses and other current liabilities $ 15,904 $ 15,022

Loan Arrangement with Former Re

Loan Arrangement with Former Related Party	12 Months Ended
	Dec. 31, 2019
Related Party Transactions [Abstract]
Loan Arrangement with Former Related Party	6. Loan Arrangement with Former Related Party In October 2007, the Company entered into a loan agreement with The Mann Group LLC (“The Mann Group”), which has been amended from time to time (including in August 2019 – see Note 7 – Borrowings). During his lifetime, Alfred Mann controlled The Mann Group, and also served as the Company’s chief executive officer until January 2015 and chairman until February 2016. Following Mr. Mann’s death in February 2016, control of The Mann Group was assumed by the trustees of the Alfred E. Mann Living Trust (the sole member and managing director of The Mann Group). None of the trustees is a member of the Company’s management or has the ability to influence the Company. At the time of Mr. Mann’s death, he beneficially owned approximately 36% of the outstanding shares of the Company’s common stock, including those held by The Mann Group. Over the three years following Mr. Mann’s death, the trustees of The Mann Group disposed of a substantial portion of these holdings. The Company has been informed that The Mann Group currently holds approximately 9.3 million shares as of December 31, 2019, which represents less than 5% of the Company’s outstanding common stock. The Company reserved an additional 14,000,000 shares for issuance to The Mann Group upon the conversion of outstanding amounts under the Mann Group convertible note. The Mann Group convertible note contains a provision that limits conversion to the extent that doing so would result in The Mann Group beneficially owning in excess of 9.99% (19.99% upon 65 days’ written notice from The Mann Group) of the outstanding shares of the Company’s common stock. Given that the trustees of the Alfred Mann Living Trust have no influence over, or involvement in the operations of, the Company, the Company has ceased to identify The Mann Group as a related party in its consolidated financial statements. Specifically, the consolidated balance sheet reflects $70.0 million in carrying amount in respect of the Mann Group promissory notes whereas the Company’s Form 10-K filed on February 26, 2019 reflected $72.1 million as related party notes and $6.8 million as accrued interest due to related party in the corresponding consolidated balance sheet as of December 31, 2018.

Borrowings

Borrowings	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Borrowings	7. Borrowings Carrying amount of borrowings consist of the following (in thousands): December 31, 2019 2018 Mann Group promissory notes $ 70,020 $ 72,089 MidCap Credit Facility 38,851 — Senior notes 10,028 19,099 Deerfield Credit Facility — 11,298 Total debt — net carrying amount $ 118,899 $ 102,486 During the year ended December 31, 2019, the Company discharged its obligations under the Deerfield Credit Facility, entered into the MidCap Credit Facility and restructured the obligations owed to its other lenders. The following table provides a summary of the Company’s debt and key terms: December 31, 2019 2018 Amount Due Annual interest rate Maturity date Conversion price Amount Due Annual interest rate Maturity date Conversion price Mann Group convertible note $35.0 million (plus $1.0 million accrued interest paid-in-kind) 7.00% November 2024 $2.50 per share $71.5 million (plus $6.8 million accrued interest paid-in-kind) 5.84 % July 2021 $4.00 per share Mann Group non- convertible note $35.1 million (plus $1.0 million accrued interest paid-in-kind) 7.00% November 2024 N/A — — — — MidCap Credit Facility $40.0 million one-month LIBOR (2% floor) plus 6.75% August 2024 N/A — — — — 2024 convertible notes $5.0 million 5.75% November 2024 $3.00 per share $18.7 million 5.75 % October 2021 $5.15 per share June 2020 note $2.6 million — June 2020 N/A — — — — December 2020 note $2.6 million — December 2020 N/A — — — — Deerfield Credit Facility — — — — $4.0 million 9.75 % July 2019 N/A — — — — $5.0 million 9.75 % August 2019 N/A — — — — $2.5 million 8.75 % May 2019 N/A The maturities of our borrowings as of December 31, 2019 are as follows (in thousands): Amounts 2020 $ 5,262 2021 4,444 2022 13,333 2023 13,333 2024 83,940 Thereafter — Total principal payments 120,312 Unamortized discount (539 ) Debt issuance costs (874 ) Total debt $ 118,899 Deerfield Facility Financing Obligation – On July 1, 2013, the Company entered into a facility agreement (the “Deerfield Credit Facility”) with Deerfield Private Design Fund II, L.P. and Deerfield Private Design International II, L.P. (collectively, “Deerfield”), which permitted it to borrow $160.0 million through the issuance of 9.75% notes due 2019 (“2019 notes”), $100.0 million of which were converted into shares of the Company’s common stock during 2013 and 2014. The Company and Deerfield amended the Deerfield Credit Facility in 2014 to permit the Company to borrow an additional $20.0 million through the issuance of 8.75% notes (“Tranche B notes”). The remaining $80.0 million in principal amount that was not converted during 2013 and 2014 ($60.0 million in 2019 notes and $20.0 million in Tranche B notes) was subject to a repayment schedule that began in July 2016 and ended in August 2019. By June 30, 2019, the Company had repaid all amounts owed under the Tranche B notes and owed approximately $9.0 million in respect of outstanding 2019 notes. On July 18, 2019, the Company entered into an exchange agreement with Deerfield pursuant to which, among other things, the Company (i) repaid approximately $2.4 million in aggregate principal amount of 2019 notes plus all accrued and unpaid interest, and (ii) issued an aggregate of 1,514,423 shares of the Company’s common stock to Deerfield in exchange for approximately $1.6 million in aggregate principal amount of 2019 notes. On August 6, 2019, the Company entered into an exchange agreement with Deerfield pursuant to which, among other things, the Company (i) repaid $2.0 million of the aggregate principal amount of 2019 notes plus accrued and unpaid interest, (ii) issued an aggregate of 2,678,571 shares of the Company’s common stock to Deerfield in exchange for $3.0 million in aggregate principal amount of 2019 notes and (iii) canceled the 2019 notes. As of December 31, 2019, the Deerfield Credit Facility was paid in full. The unamortized debt issuance costs and debt discount were zero and $0.2 million as of December 31, 2019 and 2018, respectively. Milestone Rights — As of December 31, 2019 and 2018, the remaining Milestone Rights liability balance was $7.3 million and $8.9 million, respectively, which was based on initial fair value estimates calculated using the income approach and reduced by milestone achievement payments made. During the third quarter of 2019, the Company achieved the first Afrezza net sales milestone specified in the Milestone Agreement. As a result, the Company delivered a milestone event notice to the Milestone Purchasers and made a payment of $5.0 million in the fourth quarter of 2019. The carrying value of this Milestone Rights liability was $1.6 million, which represented the fair value related to this payment, determined in 2013 (the most recent measurement date). Accordingly, $1.6 million was recorded as a reduction to the current Milestone Rights liability and $3.4 million was recognized as interest expense. The remaining Milestone Right liability of $7.3 million remains non-current as of December 31, 2019. The Milestone Agreement includes customary representations and warranties and covenants by the Company, including restrictions on transfers of intellectual property related to Afrezza. The Milestone Rights are subject to acceleration in the event the Company transfers its intellectual property related to Afrezza in violation of the terms of the Milestone Agreement. The Company initially recorded the Milestone Rights at their estimated fair value. MidCap Credit Facility — I n August 2019, the Company closed the MidCap Credit Facility, which provides a secured term loan facility in an aggregate principal amount of up to $75.0 million. The Company borrowed the first advance of $40.0 million (“Tranche 1”) on August 6, 2019. Under the terms of the MidCap Credit Facility, the second advance of $10.0 million (“Tranche 2”) will be available to the Company until April 15, 2020, subject to the satisfaction of certain conditions, including achieving Afrezza net revenue of at least $30.0 million on a trailing twelve month basis. Under the terms of the MidCap Credit Facility, the third advance of $25.0 million (“Tranche 3”) will be available to the Company until June 30, 2021, subject to the satisfaction of certain milestone conditions associated with Afrezza net revenue and certain milestone conditions related to the Company’s collaboration with United Therapeutics (see Note 8 – Collaborations and Licensing Arrangements). I n addition, unamortized debt issuance costs were $0.8 million and unamortized debt discount was $0.3 million as of December 31, 2019. In December 2019, the Company entered into an Amendment No. 1 to the MidCap Credit Facility, pursuant to which the parties agreed to (i) amend the financial covenant relating to trailing twelve month minimum Afrezza Net Revenue (as defined in the MidCap Credit Facility) requirements, (ii) add a condition to the third advance of $25.0 million that requires the Company achieve certain amounts of Afrezza Net Revenue, and (iii) increase the exit fee from 6.00% to 7.00% of the principal amount of all term loans advanced to the Company under the MidCap Credit Facility. Tranche 1 and, if borrowed, Tranche 2 and Tranche 3, each accrue interest at an annual rate equal to one-month LIBOR plus 6.75%, subject to a one-month LIBOR floor of 2.00%. Interest on each term loan advance is due and payable monthly in arrears. Principal on each term loan advance under Tranche 1 and Tranche 2 is payable in 36 equal monthly installments beginning September 1, 2021, until paid in full on August 1, 2024, and principal on each term loan advance under Tranche 3 is payable beginning on the later of (i) September 1, 2021, and (ii) the first day of the first full calendar month immediately following such term loan advance, in an amount equal to the outstanding term loan advance in respect of Tranche 3 divided by the number of full calendar months remaining before August 1, 2024. The Company has the option to prepay the term loans, in whole or in part, subject to early termination fees in an amount equal to 3.00% of principal prepaid if prepayment occurs on or prior to the first anniversary of the closing date, 2.00% of principal prepaid if prepayment occurs after the first anniversary of the closing date but on or prior to the second anniversary of the closing date, and 1.00% of principal prepaid if prepayment occurs after the second anniversary of the closing date and prior to or on the third anniversary of the closing date. In connection with execution of the MidCap Credit Facility, the Company paid MidCap a $0.4 million origination fee. The Company’s obligations under the MidCap Credit Facility are secured by a security interest on substantially all of its assets, including intellectual property. The MidCap Credit Facility contains customary affirmative covenants and customary negative covenants limiting the Company’s ability and the ability of the Company’s subsidiaries to, among other things, dispose of assets, undergo a change in control, merge or consolidate, make acquisitions, incur debt, incur liens, pay dividends, repurchase stock and make investments, in each case subject to certain exceptions. The Company must also comply with a financial covenant relating to trailing twelve month minimum Afrezza net revenue, tested on a monthly basis, and a minimum cash covenant of $15.0 million at all times prior to the funding of Tranche 2, and $20.0 million at all times following the funding of Tranche 2 and Tranche 3. As of December 31, 2019, the Company was in compliance with the financial and minimum cash covenants. The MidCap Credit Facility also contains customary events of default relating to, among other things, payment defaults, breaches of covenants, a material adverse change, listing of the Company’s common stock, bankruptcy and insolvency, cross defaults with certain material indebtedness and certain material contracts, judgments, and inaccuracies of representations and warranties. Upon an event of default, the agent and the lenders may declare all or a portion of the Company’s outstanding obligations to be immediately due and payable and exercise other rights and remedies provided for under the MidCap Credit Facility. During the existence of an event of default, interest on the term loans could be increased by 2.00%. The Company also agreed to issue warrants to purchase shares of the Company’s common stock (the “MidCap warrants”) upon the drawdown of each term loan advance under the MidCap Credit Facility in an aggregate amount equal to 3.25% of the amount drawn, divided by the exercise price per share for that tranche. The exercise price per share is equal to the volume-weighted average closing price of the Company’s common stock for the ten business days immediately preceding the second business day before the issue date. As a result of Tranche 1, the Company issued warrants to purchase an aggregate of 1,171,614 shares of the Company’s common stock, at an exercise price equal to $1.11 per share. The MidCap warrants are immediately exercisable and expire on the earlier to occur of the seventh anniversary of the respective issue date or, in certain circumstances, the closing of a merger, sale or other consolidation transactions in which the consideration is cash, stock of a publicly traded acquirer, or a combination thereof. The Company determined that these warrants met the criteria for equity classification and accounted for such warrants in additional paid-in capital. Senior Notes — As of December 31, 2019 and 2018, there was $10.2 million and $18.7 million, respectively, of principal amount of senior notes outstanding. In August 2019, the Company entered into a privately-negotiated exchange agreement with , among other things, (i) repaid $1.5 million in cash to such holder, (ii) issued 4,017,857 shares of the Company’s common stock to such holder (at a conversion price of $1.12 per share), (iii) issued the 2024 convertible notes to such holder in the principal amount of $5.0 million and (iv) issued the notes the aggregate principal amount of $5.2 million, all in exchange for the cancellation of the $18.7 million in principal amount of the 2021 notes. The 2020 notes may be prepaid at any time on or prior to their respective maturity dates of June 30, 2020 and December 31, 2020 at the option of the Company. In addition, the Company may elect to pay the 2020 notes at any time on or prior to their respective maturity dates, if certain conditions are met, in shares of the Company’s common stock at a price per share equal to the last reported sale price on the trading day immediately prior to the payment date. The 2024 convertible notes were issued pursuant to an indenture, dated as of August 6, 2019, between the Company and U.S. Bank National Association, as trustee (the “Indenture”). The 2024 convertible notes are the Company’s general, unsecured obligations, and are subordinated in right of payment to the indebtedness incurred pursuant to the MidCap Credit Facility. The 2024 convertible notes rank equally in right of payment with the Company’s other unsecured senior debt. The 2024 convertible Notes accrue interest at the rate of 5.75% per year on the principal amount, payable semiannually in arrears on February 15 and August 15 of each year, beginning February 15, 2020, with interest accruing from August 6, 2019. Interest on the 2024 convertible notes will be payable in cash or, at the option of the Company if certain conditions are met, in shares of the Company’s common stock at a price per share equal to the last reported sale price on the trading day immediately prior to the interest payment date. The 2024 convertible notes will mature on the earlier of (i) November 4, 2024 or (ii) the 91 st The 2024 convertible notes will be convertible, at the option of the holder, at any time on or prior to the close of business on the business day immediately preceding the stated maturity date, into shares of the Company’s common stock at a conversion rate of 333.3333 shares per $1,000 principal amount of 2024 convertible notes, which is equal to a conversion price of approximately $3.00 per share. If certain bankruptcy and insolvency-related events of default occur, the principal of, and accrued and unpaid interest on, all of the then outstanding 2024 convertible notes shall automatically become due and payable. If an event of default other than certain bankruptcy and insolvency-related events of defaults occurs and is continuing, the Trustee or the holders of at least 25% in aggregate principal amount of the then-outstanding 2024 convertible notes, by written notice to the Trustee, may declare the 2024 convertible notes due and payable at their principal amount plus any accrued and unpaid interest, and thereupon the Trustee may, at its discretion, proceed to protect and enforce the rights of the holders by the appropriate judicial proceedings. Notwithstanding the foregoing, the Indenture provides that, to the extent the Company elects, the sole remedy for an event of default relating to certain failures by the Company to comply with certain reporting covenants in the Indenture will, for the first 180 days after such event of default, consist exclusively of the right to receive additional interest on the 2024 convertible notes. If the Company undergoes certain fundamental changes, except in certain circumstances, each holder of convertible notes will have the option to require the Company to repurchase all or any portion of that holder’s convertible notes. The fundamental change repurchase price will be 100% of the principal amount of the convertible notes to be repurchased plus accrued and unpaid interest, if any. The Company may elect at its option to cause all or any portion of the 2024 in equals or As a result of the exchange of the senior convertible notes, the Company recorded $3.1 million as an extinguishment gain. The unamortized premium was zero and $0.4 million as of December 31, 2019 and 2018, respectively. Mann Group promissory notes — In August 2019, the Company entered into a privately-negotiated exchange agreement with The Mann Group, pursuant to which, among other things, the Company (i) repaid $3.0 million in cash to The Mann Group, (ii) issued 7,142,857 shares of the Company’s common stock to The Mann Group (at a conversion price of $1.12 per share), (iii) issued the Mann Group convertible note to the Mann Group in an aggregate principal amount of $35.0 million and (iv) issued a new non- convertible promissory note the Mann Group non-convertible note to the Mann Group in an aggregate principal amount of $35.1 million, all in exchange for the cancellation of the $71.5 million in principal and approximately $9.5 million in accrued interest paid-in-kind under the Mann Group loan arrangement. The Mann Group convertible note and Mann Group non-convertible note each accrue interest at the rate of 7.00% per year on the principal amount, payable quarterly in arrears on the first day of each calendar quarter beginning October 1, 2019. The Mann Group convertible note will mature on November 3, 2024. The principal and any accrued and unpaid interest under the Mann Group convertible note may be converted, at the option of the Mann Group, at any time on or prior to the close of business on the business day immediately preceding the stated maturity date, into shares of the Company’s common stock at a conversion rate of 400 shares per $1,000 of principal and/or accrued and unpaid interest, which is equal to a conversion price of $2.50 per share. The conversion rate will be subject to adjustment under certain circumstances described in the Mann Group convertible note. Interest on the Mann Group convertible note will be payable in kind by adding the amount thereof to the principal amount; provided that with respect to interest accruing from and after January 1, 2021, the Company may, at its option, elect to pay any such interest on any interest payment date, if certain conditions are met, in shares of the Company’s common stock at a price per shall equal to the last reported sale price on the trading day immediately prior to the payment date. The Mann Group non-convertible note will mature on the earlier of (i) November 3, 2024 or (ii) the 90th day after the repayment in full, and termination and discharge of all obligations (other than contingent indemnity obligations) under the MidCap Credit Facility. Interest on the Mann Group non-convertible note will be payable in kind by adding the amount thereof to the principal amount; provided that the Company may, at its option, elect to pay any such interest on any interest payment date, if certain conditions are met, in shares of the Company’s common stock at a price per shall equal to the last reported sale price on the trading day immediately prior to the interest payment date. The Company recorded $0.4 million as an extinguishment gain. The unamortized premium and unaccreted debt issuance costs was zero and $0.6 million as of December 31, 2019 and 2018, respectively. Amortization of the premium and accretion of debt issuance costs related to all borrowings for the years ended December 31, 2019 and 2018 are as follows (in thousands): Year Ended December 31, 2019 2018 Amortization of debt premium $ (1,049 ) $ (339 ) Amortization of debt discount 295 1,155 Accretion expense — debt issuance cost (111 ) (69 ) See Note 6 — Loan Arrangement with Former Related Party for additional information on the Company’s loan arrangements with the Mann Group.

Collaboration and Licensing Arr

Collaboration and Licensing Arrangements	12 Months Ended
	Dec. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Collaboration and Licensing Arrangements	8. Collaboration and Licensing Arrangements Revenue from collaborations and services for the years ended December 31, 2019 and 2018 are as follows (in thousands): Year Ended December 31, 2019 2018 UT License Agreement $ 31,229 $ 6,386 UT Research Agreement 6,032 3,758 Receptor CLA 250 341 Cipla distribution agreement 148 98 Biomm distribution agreement 75 — Total revenue from collaborations and services $ 37,734 $ 10,583 United Therapeutics License Agreement – In September 2018, the Company and United Therapeutics Corporation (“United Therapeutics” or “UT”) entered into an exclusive global license and collaboration agreement (the “UT License Agreement”) for the rights to the Company’s dry powder formulation of treprostinil (“TreT”) and associated inhalation delivery devices. Under the UT License Agreement, UT is responsible for global development, regulatory and commercial activities with respect to TreT. The Company is responsible for manufacturing clinical supplies and commercial supplies of TreT. Under the terms of the UT License Agreement, the Company received an upfront payment of $45.0 million in October 2018 and two $12.5 million milestone payments in 2019. The Company may receive additional milestone payments of up to $25.0 million upon the achievement of specified development targets. The Company will also be entitled to receive low double-digit royalties on net sales of TreT. UT, at its option, may expand the scope of the products covered by the UT License Agreement to include products with certain other active ingredients for the treatment of pulmonary arterial hypertension. Each such optioned product would be subject to UT’s payment to the Company of up to $40.0 million in additional option exercise and development milestone payments, as well as a low double-digit royalty on net sales of any such product. The Company recognizes revenue on a ratable basis from October 2018 through December 2021 — the estimated date when its performance obligations for development activities under the UT License Agreement will be substantially completed. At the inception of the agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables include the license, supply of product to be used in clinical development, and certain research services upon achievement of specified development targets. Due to the specialized and unique nature of these services and their direct relationship with the license, the Company has determined that these deliverables represent one distinct bundle and thus, one performance obligation. The Company also determined that UT’s option to expand the scope of the products to include products with other active ingredients is not a material right, and thus, not a performance obligation at the onset of the agreement. The consideration for the option will be accounted for upon exercise of the option. The Company expects to complete the activities specified in the development plan and to achieve the remaining milestone events for total consideration of approximately $101.4 million, which includes an upfront payment, four milestone payments and various pass-through costs. Future commercial supply remains at UT’s option and is valued at a stand-alone selling price and, therefore, is not accounted for under the current arrangement. The Company believes that this method best reflects the measure of progress toward complete satisfaction of the performance obligation. Deferred revenue related to the UT License Agreement is being recognized in net revenue – collaborations over a 13-quarter period ending December 31, 2021, which represents the estimated period to satisfy the performance obligation. As of December 31, 2019, the total deferred revenue for the UT License Agreement consisted of $38.4 million, of which $31.9 million is current and $6.5 million is long term. Deferred revenue is classified as part of current or long-term liability in the accompanying consolidated balance sheets based on the Company’s estimate of the portion of the performance obligation that will be completed within the next 12 months, and includes payments received as well as payments receivable. United Therapeutics Research Agreement – In September 2018, the Company and UT also entered into a research agreement (“UT Research Agreement”) for the conduct of research and consulting services in connection with multiple potential products, including evaluating the feasibility of preparing a dry powder formulation of a compound for the treatment of pulmonary hypertension outside the scope of the UT License Agreement. In addition, UT, at its option, may obtain a license to develop, manufacture and commercialize products based on specified compounds within the drug classes covered by the UT Research Agreement. Each specified compound advanced into development and commercialization under such a license would be subject to the payment to the Company of additional milestone payments of up to $30.0 million and a low double-digit royalty on net sales of such products. The Company received an upfront payment of $10.0 million in September 2018. At the inception of the UT Research Agreement, the Company identified two distinct performance obligations. The Company determined that the key deliverables of each performance obligation include (i) the development of a product prototype (including a technical feasibility report) and (ii) engineering consulting services. Due to the separately identifiable nature of these obligations, the Company has determined that these deliverables represent two distinct performance obligations. The Company also determined that UT’s option to expand the scope to include specific drug classes covered by the agreement is not a material right, and thus, not a performance obligation at the onset of the agreement. The consideration for the option will be accounted for upon exercise of the option. The Company allocated the total $10.0 million transaction price to its two distinct performance obligations based on available observable market inputs. A transaction price of $9.0 million was allocated to the product prototype and a transaction price of $1.0 million was allocated to engineering consulting services. The revenue for the product prototype is recognized using an output method (based on project milestones achieved and surveys of performance completed to date). The Company believes that this method best reflects the measure of progress toward complete satisfaction of the performance obligation. The revenue for the engineering consulting services was recognized using a ratable method until the obligation was satisfied. The Company believes that this method best reflects the measure of progress toward complete satisfaction of the performance obligation. As of December 31, 2019, the deferred revenue balance was $0.2 million, which Receptor Collaboration and License Agreement — In 2016, the Company entered into a collaboration and license agreement (the “CLA”) with Receptor Life Sciences, Inc. (“Receptor”) pursuant to which Receptor acquired an exclusive license to develop, manufacture and commercialize products that use the Company’s technology to deliver certain compounds via oral inhalation in exchange for upfront license fees, milestone payments upon the completion of certain technology transfer activities and the achievement of specified sales targets as well as royalties upon Receptor’s and its sublicensees’ sale of products. A $1.0 million license fee received in 2016 was recorded in deferred revenue from collaborations as of December 31, 2016 and is being recognized in net revenue — collaborations over four years, the estimated period over which the Company is required to satisfy the remaining performance obligations. The remaining performance obligations are to provide certain technology transfer activities. As of December 31, 2019, the deferred revenue balance was $0.3 million, which was classified as a current liability in the accompanying consolidated balance sheets. The additional payments referred to above represent variable consideration for which the Company has not recognized any revenue because it is uncertain that Receptor will be able to successfully develop, manufacture or sell product related to this license. There was no change to the accounting for this contract as a result of the initial application of the new revenue guidance since (i) the receipt of such payments is highly susceptible to factors outside of the Company’s influence, (ii) the uncertainty regarding the receipt of these payments is not expected to be resolved for years, and (iii) the Company has limited experience with similar contracts. See Note 1 – Description of Business and Note 2 –Summary of Significant Accounting Policies for additional information on the Company’s revenue recognition accounting policy. In 2017, the Company entered into a manufacturing and supply agreement with Receptor pursuant to which the Company agreed to provide certain raw materials and certain additional research and formulation consulting services to Receptor. For the years ended December 31, 2019 and 2018, the additional research and formulation services provided to Receptor were de minimis Biomm Supply and Distribution Agreement – In May 2017, the Company and Biomm entered into a supply and distribution agreement for the commercialization of Afrezza in Brazil. Under this agreement, Biomm was responsible for pursuing regulatory approvals of Afrezza in Brazil, including from the Agência Nacional de Vigilância Sanitária (“ANVISA”) and, with respect to pricing matters, from the Camara de Regulação de Mercado de Medicamentos (“CMED”), both of which have now been received. In September 2019, the Company delivered its first shipment of Afrezza to Biomm and recognized $0.7 million as commercial product sales in advance of the launch of the product in Brazil. Biomm commenced product sales in January 2020. Cipla License and Distribution Agreement — In May 2018, the Company and Cipla Ltd. (“Cipla”) entered into an exclusive agreement for the marketing and distribution of Afrezza in India and the Company received a $2.2 million nonrefundable license fee. Under the terms of the agreement, Cipla will be responsible for obtaining regulatory approvals to distribute Afrezza in India and for all marketing and sales activities of Afrezza in India. The Company is responsible for supplying Afrezza to Cipla. The Company has the potential to receive certain additional regulatory milestone payments, minimum purchase commitment revenue and royalties on Afrezza sales in India once cumulative gross sales have reached a specified threshold. The nonrefundable licensing fee was recorded in deferred revenue and is being recognized in net revenue – collaborations over 15 years, representing the estimated period to satisfy the performance obligation. The additional milestone payments represent variable consideration for which the Company has not recognized any revenue because of the uncertainty of obtaining marketing approval. The Company also recognized $0.2 million as income tax expense for a payment made to the India tax authority in 2018. As of December 31, 2019, the deferred revenue balance was $1.9 million, of which $0.1 million is classified as current and $1.8 million is classified as long term in the accompanying consolidated balance sheets. AMSL Distribution Agreement – In May 2019, the Company entered into an exclusive marketing and distribution agreement with the AMSL Diabetes division of Australasian Medical & Scientific Ltd. (“AMSL Diabetes”) for the commercialization of Afrezza in Australia. Under the terms of this agreement, AMSL Diabetes is responsible for obtaining regulatory and reimbursement approvals to distribute Afrezza in Australia. Upon regulatory approval, AMSL Diabetes will conduct sales, marketing, and customer support and distribution activities whereas the Company will be responsible for the supply and manufacturing of Afrezza.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	12 Months Ended
	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	9. Fair Value of Financial Instruments The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level input that is significant to the overall fair value measurement. The Company uses the exit price method for estimating the fair value of loans for disclosure purposes. The carrying amounts reported in the accompanying consolidated financial statements for cash, accounts receivable, accounts payable, and accrued expenses and other current liabilities (excluding the Milestone Rights liability) approximate their fair value due to their relatively short maturities. The fair value of the cash equivalents, MidCap Credit Facility, 2020 notes, and Milestone Rights liabilities Cash Equivalents and Restricted Cash — Cash equivalents consist of highly liquid investments with original or remaining maturities of 90 days or less at the time of purchase that are readily convertible into cash. As of December 31, 2019 and 2018, the Company held $29.9 million and $71.2 million, respectively, of cash and cash equivalents. The Company held $0.3 million and $0.5 million in restricted cash as of December 31, 2019 and 2018, respectively. Both are comprised of money market funds. Restricted cash is used to collateralize a letter of credit. The fair value of these money market funds was determined by using quoted prices for identical investments in an active market (Level 1 in the fair value hierarchy). Short-term investments — Short-term investments consist of highly liquid investments that are intended to facilitate liquidity and capital preservation. As of December 31, 2019, the Company held $20.0 million of short-term investments in U.S. Treasury bills or notes. The Company did not have short-term investments as of December 31, 2018. The fair value of short-term investments approximate their carrying value. The fair value measurement is based on a market approach using quoted market values (Level 1 in the fair value hierarchy). The fair value measurement of debt instruments is based on a discounted cash flow model and is sensitive to the change in yield (Level 3 in the fair value hierarchy): Hypothetical Change in Yield Hypothetical Change in Notes Payable Yield % Change Hypothetical Yield FV of Notes FV $ Change % Change (in millions) Mann Group promissory notes: (with conversion feature) 29.0 % 2 % 31.0 % $ 46.2 $ 44.1 $ (2.1 ) -4.5 % 29.0 % -2 % 27.0 % $ 46.2 $ 48.5 $ 2.3 5.0 % 29.0 % 4 % 33.0 % $ 46.2 $ 42.2 $ (4.0 ) -8.7 % 29.0 % -4 % 25.0 % $ 46.2 $ 51.0 $ 4.8 10.4 % Senior notes: (with conversion feature) 29.0 % 2 % 31.0 % $ 8.0 $ 7.8 $ (0.2 ) -2.5 % 29.0 % -2 % 27.0 % $ 8.0 $ 8.2 $ 0.2 2.5 % 29.0 % 4 % 33.0 % $ 8.0 $ 7.6 $ (0.4 ) -5.0 % 29.0 % -4 % 25.0 % $ 8.0 $ 8.4 $ 0.4 5.0 % MidCap Credit Facility 11.5 % 1 % 12.5 % $ 40.0 $ 39.0 $ (1.0 ) -2.5 % 11.5 % -1 % 10.5 % $ 40.0 $ 41.0 $ 1.0 2.5 % 11.5 % 2 % 13.5 % $ 40.0 $ 38.1 $ (1.9 ) -4.8 % 11.5 % -2 % 9.5 % $ 40.0 $ 42.1 $ 2.1 5.3 % Financial Liabilities — The following tables set forth the fair value of the Company’s financial instruments as of December 31, 2019 and 2018 (in millions): December 31, 2019 Fair Value Carrying Amount Significant Unobservable Inputs (Level 3) Total Fair Value Financial liabilities: MidCap Credit Facility $ 38.9 $ 40.0 $ 40.0 2024 convertible notes 5.0 3.7 3.7 June 2020 note 2.5 2.3 2.3 December 2020 note 2.5 2.0 2.0 Mann Group promissory notes 70.0 46.2 46.2 Milestone Rights 7.3 16.4 16.4 Total financial liabilities $ 126.2 $ 110.6 $ 110.6 December 31, 2018 Fair Value Carrying Value Significant Unobservable Inputs (Level 3) Total Fair Value Financial liabilities: Deerfield Credit Facility $ 11.3 $ 11.4 $ 11.4 Senior convertible notes 19.1 17.5 17.5 Mann Group promissory notes 72.1 55.0 55.0 Milestone Rights 8.9 18.1 18.1 Total financial liabilities $ 111.4 $ 102.0 $ 102.0 Milestone Rights Liability — The fair value measurement of the Milestone Rights liability is sensitive to the discount rate and the timing of achievement of milestones. The Company utilized Monte-Carlo Simulation Method to simulate the Net Sales under a neutral framework to estimate the payment. The Company then discounted the future expected payments at cost of debt with a term equal to the simulated time to payout based on cumulative sales. Embedded Derivatives — The Company identified and evaluated a number of embedded features in the notes issued under the Deerfield Credit Facility to determine if they represented embedded derivatives that are required to be separated from the notes and accounted for as freestanding instruments. The Company analyzed the Tranche B notes and identified embedded derivatives, which required separate accounting. All of the embedded derivatives were determined to have a value at December 31, 2018 and no value as of December 31, 2019 due to the repayment of the Deerfield Credit Facility in August 2019.

Common and Preferred Stock

Common and Preferred Stock	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Common and Preferred Stock	10. Common and Preferred Stock The Company is authorized to issue 280,000,000 shares of common stock, par value $0.01 per share, and 10,000,000 shares of undesignated preferred stock, par value $0.01 per share, issuable in one or more series as designated by the Company’s board of directors. No other class of capital stock is authorized. As of December 31, 2019 and 2018, 211,787,573 and 187,029,967 shares of common stock, respectively, were issued and outstanding and no shares of preferred stock were outstanding. In February 2018, the Company entered into a controlled equity offering sales agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor Fitzgerald”), as sales agent, pursuant to which the Company may offer and sell, from time to time, through Cantor Fitzgerald, shares of the Company’s common stock having an aggregate offering price of up to $50.0 million or such other amount as may be permitted by the Sales Agreement. Under the Sales Agreement, Cantor Fitzgerald may sell shares by any method deemed to be an “ ” In April 2018, the Company entered into securities purchase agreements with certain institutional investors. Pursuant to the terms of the purchase agreements, the Company sold to the purchasers in a registered offering an aggregate of 14,000,000 shares of the Company’s common stock and warrants to purchase up to an aggregate of 14,000,000 shares of the Company’s common stock at a combined purchase price of $2.00 per share and accompanying warrant. The shares of common stock and the warrants were immediately separable. The warrants became exercisable at a price of $2.38 per share beginning on October 9, 2018 and expired unexercised on April 9, 2019. The net proceeds to the Company from the offering were approximately $26.4 million. The offering closed on April 9, 2018. In December 2018, the Company entered into an underwriting agreement with Leerink Partners LLC relating to the issuance and sale in a public offering of 26,666,667 shares of the Company’s common stock and warrants to purchase up to an aggregate of 26,666,667 shares of the Company’s common stock (the “December warrants”) at a combined purchase price of $1.50 per share and accompanying warrant. The shares of common stock and the December warrants were immediately separable. The December warrants were immediately exercisable at issuance at a price of $1.60 per share and had an expiry date of December 26, 2019. The net proceeds to the Company from the offering were approximately $37.3 million. For the year ended December 31, 2018, the Company received

Earnings Per Common Share ("EPS

Earnings Per Common Share ("EPS")	12 Months Ended
	Dec. 31, 2019
Earnings Per Share [Abstract]
Earnings Per Common Share ("EPS")	11. Earnings per Common Share (“EPS”) Basic EPS excludes dilution for potentially dilutive securities and is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period. Diluted EPS reflects the potential dilution under the treasury method that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. For periods where the Company has presented a net loss, potentially dilutive securities are excluded from the computation of diluted EPS as they would be antidilutive. The following tables summarize the components of the basic and diluted EPS computations (in thousands, except per share amounts): Year Ended December 31, 2019 2018 EPS — basic and diluted: Net loss (numerator) $ (51,903 ) $ (86,975 ) Weighted average common shares (denominator) 195,584 144,136 Net loss per share $ (0.27 ) $ (0.60 ) Common shares issuable represents incremental shares of common stock which consist of stock options, restricted stock units, warrants, and shares that could be issued upon conversion of the senior convertible notes and the Mann Group promissory notes. Potentially dilutive securities outstanding that are considered antidilutive are summarized as follows (in shares): Year Ended December 31, 2019 2018 Exercise of common stock options 14,135,681 10,976,118 Conversion of convertible notes payable to former related party into common stock 14,000,000 21,909,541 Exercise of warrants associated with public offering 7,250,000 26,666,667 Exercise of warrants associated with Midcap Credit Facility 1,171,614 — Conversion of convertible notes into common stock 1,666,667 3,629,627 Vesting of restricted stock units 1,057,047 691,266 Employee stock purchase plan 369,979 307,395 Exercise of common stock warrants 31,851 31,851 Exercise of warrants associated with direct placement — 14,000,000 Total 39,682,839 78,212,465

Stock Award Plans

Stock Award Plans	12 Months Ended
	Dec. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Award Plans	12. Stock Award Plans On May 16, 2018, the Company adopted the 2018 Equity Incentive Plan (the “2018 Plan”) as the successor to and continuation of the 2013 Equity Incentive Plan (the “2013 Plan”) and the 2004 Equity Incentive Plan (the “2004 Plan”). The 2018 Plan consists of 12.0 million additional shares and the number of unallocated shares remaining available for grant for new awards under the 2013 Plan and the 2004 Plan. The 2018 Plan provides for the granting of stock awards including stock options and restricted stock units to employees, directors and consultants. No additional awards will be granted under the 2013 Plan, the 2004 Plan or the 2004 Non-Employee Directors’ Stock Option Plan (the “NED Plan”) as all future awards will be made out of the 2018 Plan. The Company’s board of directors determines eligibility, vesting schedules and criteria, and exercise prices for stock awards granted under the 2018 Plan. Options and restricted stock unit awards under the 2018 Plan, the 2013 Plan and the 2004 Plan expire not more than ten years from the date of the grant and are exercisable upon vesting. Stock options that vest over time generally vest over four years. Current time-based vesting stock option grants vest and become exercisable at the rate of 25% after one year and ratably on a monthly basis over a period of 36 months thereafter. Restricted stock units with time-based vesting generally vest at a rate of 25% per year over four years with consideration satisfied by service to the Company. The Company also issues stock awards with performance conditions. The following table summarizes information about the Company’s stock-based award plans as of December 31, 2019: Outstanding Options Outstanding Restricted Stock Units Shares Available for Future Issuance 2004 Equity Incentive Plan 451,149 — — 2013 Equity Incentive Plan 4,714,169 393,309 — 2018 Equity Incentive Plan 8,934,586 663,738 4,710,565 2004 Non-Employee Directors’ Stock Option Plan 35,777 — — Total 14,135,681 1,057,047 4,710,565 Share-based payment transactions are recognized as compensation cost based on the fair value of the instrument on the date of grant. The Company uses the Black-Scholes option valuation model to estimate the grant date fair value of employee stock options. The expected term of an option granted is based on combining historical exercise data with expected weighted time outstanding. Expected weighted time outstanding is calculated by assuming the settlement of outstanding awards is at the midpoint between the remaining weighted average vesting date and the expiration date. During the years ended December 31, 2019 and 2018, the Company recorded stock-based compensation expense of $6.2 million, $6.9 million, respectively. Total stock-based compensation expense recognized in the accompanying consolidated statements of operations is included in the following categories (in thousands): Year Ended December 31, 2019 2018 Cost of goods sold $ 601 $ 379 Research and development 356 1,203 Selling, general and administrative 4,508 5,275 Cost of revenue — collaborations and services 738 — Total $ 6,203 $ 6,857 The expected volatility assumption used in the Company’s Black-Sholes option valuation model is based on an assessment of the historical volatility derived from an analysis of historical trade activity. The Company has selected risk-free interest rates based on U.S. Treasury securities with an equivalent expected term in effect on the date the options were granted. Additionally, the Company uses historical data and management judgment to estimate stock option exercise behavior and employee turnover rates to estimate the number of stock option awards that will eventually vest. The Company calculated the fair value of employee stock options granted during the years ended December 31, 2019 and 2018 using the following assumptions: Year Ended December 31, 2019 2018 Risk-free interest rate 1.52% — 2.51% 2.63% — 3.11% Expected lives 6.20 — 9.37 years 5.90 — 7.19 years Volatility 93.05% — 94.25% 92.68% — 93.62% Dividends — — The following table summarizes information about stock options outstanding: Number of Shares Weighted Average Exercise Price per Share Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value ($000) Outstanding at January 1, 2019 10,976,118 $ 5.75 7.83 $ — Granted 5,613,253 1.32 Exercised (67,461 ) 1.10 Forfeited (1,395,644 ) 2.25 Expired (990,585 ) 17.07 Outstanding at December 31, 2019 14,135,681 $ 3.09 7.84 $ 182 Exercisable at December 31, 2019 4,554,661 $ 6.20 6.00 $ 86 The weighted average grant date fair value of the stock options granted during the years ended December 31, 2019 and 2018 was $1.32 and $1.51, respectively. The total intrinsic value of options exercised during the year ended December 31, 2019 and 2018 was de minimis Cash received from the exercise of options during the year ended December 31, 2019 was approximately $0.1 million and for the year ended December 31, 2018 the cash received was de minimis As of December 31, 2019 and 2018, the Company recognized a de minimis A summary of restricted stock unit activity for the year ended December 31, 2019 is presented below: Number of Shares Weighted Average Grant Date Fair Value per Share Outstanding at January 1, 2019 691,266 $ 3.72 Granted 1,293,690 1.42 Vested (804,105 ) 2.33 Forfeited (123,804 ) 2.06 Outstanding at December 31, 2019 1,057,047 2.16 Total fair value of restricted stock units vested during the years ended December 31, 2019 and 2018 was $1.1 million and $1.4 million, respectively. Intrinsic value of restricted stock units vested is measured using the closing share price on the day prior to the vest date. The total grant date fair value of restricted stock units outstanding as of December 31, 2019 and 2018 was $2.3 million and $2.4 million, respectively. As of December 31, 2019, there was $9.9 million of unrecognized compensation expense related to options and performance-based options and $0.6 million of unrecognized compensation expense related to restricted stock units, which are expected to be recognized over the weighted average vesting period of 1.0 to 2.9 years. The Company evaluates stock awards with performance conditions as to the probability that the performance conditions will be met and uses that information to estimate the date at which those performance conditions will be met in order to properly recognize stock-based compensation expense over the requisite service period.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2019
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	13. Commitments and Contingencies Guarantees and Indemnifications — In the ordinary course of its business, the Company makes certain indemnities, commitments and guarantees under which it may be required to make payments in relation to certain transactions. The Company, as permitted under Delaware law and in accordance with its Bylaws, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company’s request in such capacity. The term of the indemnification period is for the officer’s or director’s lifetime. The maximum amount of potential future indemnification is unlimited; however, the Company has a director and officer insurance policy that may enable it to recover a portion of any future amounts paid. The Company believes the fair value of these indemnification agreements is minimal. The Company has not recorded any liability for these indemnities in the accompanying consolidated balance sheets. However, the Company accrues for losses for any known contingent liability, including those that may arise from indemnification provisions, when future payment is probable and the amount can be reasonably estimated. No such losses have been recorded to date. Litigation — The Company is subject to legal proceedings and claims which arise in the ordinary course of its business. As of December 31, 2019, the Company believes that the final disposition of such matters will not have a material adverse effect on the financial position, results of operations or cash flows of the Company and no accrual has been recorded. The Company maintains liability insurance coverage to protect the Company’s assets from losses arising out of or involving activities associated with ongoing and normal business operations. The Company records a provision for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Company’s policy is to accrue for legal expenses in connection with legal proceedings and claims as they are incurred. Following the public announcement in January 2016 of the election by sanofi-aventis U.S. LLC (“Sanofi”) to terminate a license and collaboration agreement (the “Sanofi License Agreement”) between the Company and Sanofi and the subsequent decline in the Company’s stock price, two motions were submitted to the district court at Tel Aviv, Economic Department for the certification of a class action against the Company and certain of its officers and directors. In general, the complaints allege that the Company and certain of its officers and directors violated Israeli and U.S. securities laws by making materially false and misleading statements regarding the prospects for Afrezza, thereby artificially inflating the price of its common stock. The plaintiffs are seeking monetary damages. In November 2016, the district court dismissed one of the actions without prejudice. In the remaining action, the district court ruled in October 2017 that U.S. law will apply to this case. The plaintiff appealed this ruling, and following an oral hearing before the Supreme Court of Israel, decided to withdraw his appeal. Subsequently, in November 2018, the Company filed a motion to dismiss the certification motion. In September 2019, the plaintiff brought a motion to amend his claim, which the court denied in January 2020. The Company will continue to vigorously defend against the claims advanced. Contingencies — In July 2013, the Company also entered into a Milestone Agreement with the Milestone Purchasers, pursuant to which the Company granted such Milestone Purchasers rights to receive payments up to $90.0 million upon the occurrence of specified strategic and sales milestones, $70.0 million of which remains payable upon achievement of such milestones (see Note 7 — Borrowings). Commitments — In July 2014, the Company entered into the Insulin Supply Agreement with Amphastar pursuant to which Amphastar manufactures for and supplies to the Company certain quantities of recombinant human insulin for use in Afrezza. Under the terms of the Insulin Supply Agreement, Amphastar is responsible for manufacturing the insulin in accordance with the Company’s specifications and agreed-upon quality standards. In August 2019, the Company and Amphastar amended the Insulin Supply Agreement to extend the term to 2026 and to restructure the annual purchase commitments. The annual purchase requirements under the amended contract are as follows: Minimum Commitment 2020 € 6.6 million 2021 € 6.6 million 2022 € 8.5 million 2023 € 10.8 million 2024 € 14.6 million 2025 € 15.5 million 2026 € 19.4 million During the year ended December 31, 2019 and 2018, the Company paid amendment fees Unless terminated earlier, the term of the Insulin Supply Agreement expires on December 31, 2026 and can be renewed for additional, successive two year terms upon 12 months’ written notice given prior to the end of the initial term or any additional two year term. The Company and Amphastar each have normal and customary termination rights, including termination for a material breach that is not cured within a specific time frame or in the event of liquidation, bankruptcy or insolvency of the other party. In addition, the Company may terminate the Insulin Supply Agreement upon two years’ prior written notice to Amphastar without cause or upon 30 days’ prior written notice to Amphastar if a controlling regulatory authority withdraws approval for Afrezza, provided, however, in the event of a termination pursuant to either of the latter two scenarios, the provisions of the Insulin Supply Agreement require the Company to pay the full amount of all unpaid purchase commitments due over the initial term within 60 calendar days of the effective date of such termination. In 2019, the Company entered into two 90-day foreign currency hedging transactions to mitigate its exposure to foreign currency exchange risks associated with then-existing insulin purchase commitments. The Company realized a de minimis Warrants - In December 2018, the Company issued the December warrants to purchase up to an aggregate of 26,666,667 shares of the Company’s common stock at an exercise price of $1.60 per share. During 2019, the Company repurchased 3,333,334 December warrants and modified 11,750,000 December warrants, of which 4,500,000 were subsequently exercised. In December 2019, 11,583,333 On August 6, 2019, in connection with the MidCap Credit Facility, the Company issued warrants to purchase an aggregate of 1,171,614 shares of the Company’s common stock, at an exercise price equal to $1.11 per share, to the lenders. Additional MidCap warrants will be issued if the Company accesses additional tranches under the MidCap Credit Facility (see Vehicle Leases – During the second quarter of 2018, the Company entered into a lease agreement with Enterprise Fleet Management Inc. for the lease of 119 vehicles. The lease requires monthly payments of approximately $83,000 per month including the cost of maintaining the vehicles, taxes and insurance. The lease commenced when the Company took possession of the majority of the vehicles in the second quarter of 2018 and expires 48 months after the delivery date. As of December 31, 2019, 29 vehicles were removed from the fleet, resulting in a fleet size of 90 vehicles; no gain or loss was recorded. The revised monthly payment inclusive of maintenance fees, insurance and taxes is $65,000 and the reduction of the right of use asset and lease obligation is approximately $0.4 million in our consolidated balance sheets. The lease expense is included in selling, general and administrative expenses in the accompanying consolidated statement of operations for the year ended December 31, 2019. Upon adoption of ASC 842, the agreement was classified as an operating lease which resulted in recording right-of-use assets and lease liabilities of approximately $1.6 million and $1.9 million, respectively, as of January 1, 2019. These amounts included approximately $1.6 million of non-current other assets and approximately $0.6 million and $1.3 million of other current liabilities and operating lease liabilities, respectively. Office Lease — On May 5, 2017, the Company executed an office lease with Russell Ranch Road II LLC for the Company’s corporate headquarters in Westlake Village, California. The office lease commenced in August 2017. The Company agreed to pay initial monthly lease payments of $40,951, subject to 3% annual increases, plus the estimated cost of maintaining the property and common areas by the landlord, with a five month concession from October 2017 through February 2018. The lease also provides for allowances for tenant alterations and maintenance. The lease expires in January 2023 and provides the Company with a five year renewal option. The lease expense is included in selling, general and administrative expenses in the accompanying consolidated statement of operations for year ended December 31, 2019 . On November 29, 2017, the Company executed an office lease with Russell Ranch Road II LLC to expand the office space for the Company’s corporate headquarters in Westlake Village, California. The office lease commenced in October 2018. The Company agreed to pay initial monthly lease payments of $35,969, subject to a 3% annual increase, plus the estimated operating cost of maintaining the property by the landlord, which are allocable based an annual assessment made by the landlord. In addition, the Company received reimbursement from the landlord of $56,325 for tenant improvements and was not required to pay a first-year common area maintenance fee. The lease expires in January 2023 and provides the Company with a five year renewal option. Upon adoption of ASC 842, this lease was classified as an operating lease which resulted in recording right-of-use assets and lease liabilities of approximately $3.2 million and $3.5 million, respectively, as of January 1, 2019. These amounts included approximately $0.9 million and $2.6 million of other current liabilities and operating lease liabilities, respectively. Operating lease costs under all operating leases including office space and equipment for the year ended December 31, 2019 was approximately $1.5 million. Cash paid for all operating leases for the year ended December 31, 2019 was $1.8 million. Rent expense under all operating leases for the year ended December 31, 2018, including office space and equipment, was approximately $0.5 million Future minimum office and vehicle lease payments as of December 31, 2019 and 2018 were as follows: December 31, 2019 2018 2019 $ — $ 1,595,421 2020 1,470,217 1,623,835 2021 1,499,484 1,653,101 2022 1,241,089 1,305,096 2023 87,957 87,957 Total $ 4,298,747 $ 6,265,410 The 2018 amounts above are inclusive of office and vehicle lease payments in order to conform to the current year’s presentation.

Employee Benefit Plans

Employee Benefit Plans	12 Months Ended
	Dec. 31, 2019
Compensation And Retirement Disclosure [Abstract]
Employee Benefit Plans	14. Employee Benefit Plans The Company administers a 401(k) savings retirement plan for its employees. The Company contributed $1.5 million and $1.0 million for the years ended December 31, 2019 and 2018, respectively.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	15. Income Taxes Loss from continuing operations before provision for income tax for the Company’s domestic and international operations was as follows (in thousands): Year Ended December 31, 2019 2018 United States $ (51,044 ) $ (84,207 ) Foreign (859 ) (2,528 ) Loss before provision for income taxes $ (51,903 ) $ (86,735 ) At December 31, 2019, the Company has concluded that it is more likely than not that the Company may not realize the benefit of its deferred tax assets due to its history of losses. There was no provision for income tax recorded for the year ended December 31, 2019 as a result of the current year losses. The provision for income taxes for the year ended December 31, 2018 was $0.2 million. The provision for income taxes relates only to withholding taxes for the year ended December 31, 2018 because the Company has incurred operating losses since inception. Accordingly, the net deferred tax assets have been fully reserved. Year Ended December 31, 2019 2018 Current U.S. federal $ — $ — U.S. state — — Non-U.S. — 240 Total current — 240 Deferred U.S. federal (8,551 ) (9,164 ) U.S. state 3,299 (1,903 ) Non-U.S. — — Total deferred (5,252 ) (11,067 ) Valuation allowance 5,252 11,067 Total $ — $ 240 Deferred income taxes reflect the tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and income tax purposes. A valuation allowance is established when uncertainty exists as to whether all or a portion of the net deferred tax assets will be realized. Components of the net deferred tax assets as of December 31, 2019 and 2018, are as follows (in thousands): December 31, 2019 2018 Deferred tax assets: Net operating loss carryforwards $ 531,970 $ 524,377 Research and development credits 80,488 81,583 Capitalized research 44 557 Milestone Rights 1,528 3,521 Accrued expenses 1,951 1,156 Loss on purchase commitment 22,167 23,194 Non-qualified stock option expense 3,128 2,551 Capitalized patent costs 4,964 5,090 Other 147 669 Lease liability 827 — Interest expense limitation 1,167 — Depreciation 21,132 22,560 Deferred Product Revenue & Costs 2,062 107 Total net deferred tax assets 671,575 665,365 Valuation allowance (670,617 ) (665,365 ) Net deferred tax assets $ 958 $ — Deferred tax liabilities: Right of use asset $ (751 ) $ — Other prepaids (207 ) — Total deferred tax liabilities (958 ) — Net deferred tax assets $ — $ — The Company’s effective income tax rate differs from the statutory federal income tax rate as follows for the years ended December 31, 2019 and 2018: Year Ended December 31, 2019 2018 Federal tax benefit rate 21.0 % 21.0 % Permanent items (3.3 ) 1.0 Tax law changes (2.7 ) (0.7 ) Stock based compensation (0.9 ) (6.5 ) Tax attribute expirations (4.0 ) (1.6 ) Foreign withholding tax — (0.3 ) Valuation allowance (10.1 ) (13.2 ) Effective income tax rate 0.0 % -0.3 % As of December 31, 2019 and 2018, management assessed the realizability of deferred tax assets. Management evaluated the need for an amount of any valuation allowance for deferred tax assets on a jurisdictional basis. This evaluation utilizes the framework contained in ASC 740, Income Taxes In concluding on the evaluation, management placed significant emphasis on guidance in ASC 740, which states that “a cumulative loss in recent years is a significant piece of negative evidence that is difficult to overcome.” Based upon available evidence, it was concluded on a more-likely-than-not basis that all deferred tax assets were not realizable as of December 31, 2019. Accordingly, a valuation allowance of $670.6 million has been recorded to offset this deferred tax asset. During the years ended December 31, 2019 and 2018, the change in the valuation allowance was $5.3 million and $11.1 million, respectively. At December 31, 2019, the Company had federal and state net operating loss carryforwards of approximately $2.1 billion and $1.3 billion available, respectively, to reduce future taxable income. $117.8 million of the federal losses do not expire and the remaining federal and state losses have started expiring, beginning in the current year through various future dates. Pursuant to Internal Revenue Code (“IRC”) Sections 382 and 383, annual use of the Company’s federal and state net operating loss and research and development credit carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period. As a result of the Company's initial public offering, an ownership change within the meaning of Internal Revenue Code Section 382 occurred in August 2004. As a result, federal net operating loss and credit carryforwards of approximately $216.0 million are subject to an annual use limitation of approximately $13.0 million. The annual limitation is cumulative and therefore, if not fully utilized in a year can be utilized in future years in addition to the Section 382 limitation for those years. We have completed a Section 382 analysis beginning from the date of our initial public offering through to the end of the previous tax year regarding whether additional limitations may be placed on the net operating loss carryforwards and other tax attributes, and no additional changes in ownership that met Section 382 study ownership change threshold has been identified through December 31, 2019. There is a risk that changes in ownership may occur in tax years after December 31, 2019. If a change in ownership were to occur, our net operating loss carryforwards and other tax attributes could be further limited or restricted. If limited, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. Due to the existence of the valuation allowance, limitations created by future ownership changes, if any, related to the Company’s operations in the U.S. will not impact the Company’s effective tax rate. At December 31, 2019, the Company had $54.2 million of U.S. federal research and development credits which expire beginning in 2024, and $26.3 million of state research and development credits. The California credits do not expire and the New Jersey credits will begin to expire in 2020. The Company also had two types of credits in Connecticut of which $15.7 million do not expire and $0.9 million will begin to expire in 2020. Due to the existence of the valuation allowance, the expiration of the research and development credits will not impact the Company’s consolidated statements of operations. The Company files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations. In the normal course of business the Company is subject to examination by taxing authorities throughout the country. These audits could include examining the timing and amount of deductions, the allocation of income among various tax jurisdictions and compliance with federal, state and local laws. The Company’s tax years since 2015 remain subject to examination by federal, state and foreign tax authorities. The Company considers its undistributed earnings of foreign subsidiaries to be permanently reinvested in foreign operations and has not provided for U.S. income taxes on such earnings. As of December 31, 2019 the Company had no undistributed earnings from its foreign subsidiaries. The Company adopted Accounting Standards Codification (“ASC”) Topic 842 – Leases, on January 1, 2019. Under Topic 842, the Company is required to recognize the assets and liabilities that arise from most operating leases on the balance sheet. Upon adoption, no change in retained earnings was recorded related to income taxes as the Company maintains a full valuation allowance. As of the implementation date, an adjustment of $0.7 million was recorded as a deferred tax liability and an adjustment of $0.7 million was recorded as a deferred tax asset. See above for more information about the non-income tax impact of the adoption of the new leasing standard. Legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act of 2017, subjects a U.S. shareholder to tax on global intangible low-taxed income (“GILTI”) earned by certain foreign subsidiaries. The FASB Staff Q&A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only.

Selected quarterly financial da

Selected quarterly financial data (unaudited)	12 Months Ended
	Dec. 31, 2019
Quarterly Financial Information Disclosure [Abstract]
Selected quarterly financial data (unaudited)	16. Selected quarterly financial data (unaudited) Summarized quarterly financial data for the years ended December 31, 2019 and 2018, are set forth in the following tables: March 31 June 30 September 30 December 31 (In thousands, except per share data) 2019 Net revenues $ 17,448 $ 15,002 $ 14,595 $ 15,993 Net loss $ (14,883 ) $ (12,387 ) $ (10,370 ) $ (14,263 ) Net loss per share — basic and diluted $ (0.08 ) $ (0.07 ) $ (0.05 ) $ (0.07 ) Weighted average common shares used to compute net loss per share — basic and diluted 187,434 188,054 199,906 206,689 2018 Net revenues $ 3,465 $ 3,893 $ 4,469 $ 16,031 Net loss $ (30,385 ) $ (22,675 ) $ (24,168 ) $ (9,747 ) Net loss per share — basic and diluted $ (0.25 ) $ (0.16 ) $ (0.16 ) $ (0.06 ) Weighted average common shares used to compute net loss per share — basic and diluted 120,911 140,054 153,597 161,397

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Business	Business — MannKind Corporation and its subsidiaries (the “Company”) is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. The Company’s only approved product, Afrezza (insulin human) Inhalation Powder, is an ultra rapid-acting inhaled insulin that was approved by the U.S. Food and Drug Administration (the “FDA”) in June 2014 to improve glycemic control in adults with diabetes. Afrezza became available by prescription in United States retail pharmacies in February 2015. Currently, the Company promotes Afrezza to endocrinologists and certain high-prescribing primary care physicians in the United States through its specialty sales force. In addition, the Company’s partner in Brazil, Biomm, commenced commercialization of Afrezza in January 2020 and the Company’s partners in India and Australia are preparing for regulatory submissions and have not yet commenced commercialization in their respective territories.
Basis of Presentation	Basis of Presentation — The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company is not currently profitable and has rarely generated positive net cash flow from operations. In addition, the Company expects to continue to incur significant expenditures for the foreseeable future in support of its manufacturing operations, sales and marketing costs for Afrezza, and development costs for product candidates in the Company’s pipeline. As of December 31, 2019, the Company had an accumulated deficit of $3.0 billion and $120.3 million of total principal amount of outstanding borrowings, with limited capital resources of $29.9 million in cash and cash equivalents and $20.0 million in short-term investments. These financial conditions raise substantial doubt about the Company’s ability to continue as a going concern. In August 2019, the Company and MannKind LLC entered into a credit and security agreement with MidCap Financial Trust (as amended, the “MidCap Credit Facility”) to recapitalize its debt structure (the “recapitalization”) (Refer to Note 7 – Borrowings for further details). The MidCap Credit Facility provides a secured term loan facility in an aggregate principal amount of up to $75.0 million, of which $40.0 million was outstanding as of December 31, 2019 and the remaining $35.0 million will become available under the following conditions: (1) $10.0 million will be available to the Company until April 15, 2020, subject to the satisfaction of certain conditions, including achieving Afrezza net revenue of at least $30.0 million on a trailing twelve month basis, and (2) the remaining $25.0 million will be available to the Company until June 30, 2021, subject to the satisfaction of certain milestone conditions associated with Afrezza net revenue and certain milestone conditions related to the Company’s collaboration with United Therapeutics (see Note 8 – Collaborations and Licensing Arrangements). Principal payments on the MidCap Credit Facility began in September 2021. In addition, the MidCap Credit Facility contains certain covenants, one of which includes a requirement to maintain a minimum of $15.0 million of unrestricted cash and cash equivalents. This amount will increase to $20.0 million if the Company draws the aforementioned additional funding that may be made available. As part of the recapitalization, the Company converted shares of common stock, made repayments on outstanding borrowings, and used some of the proceeds from the MidCap Credit Facility proceeds to: 1) Fully repay the remaining $5.0 million due on its financing facility with Deerfield Private Design Fund II L.P. and Deerfield Private Design International I L.P. 2) Pay down the Company’s obligations under the Mann Group promissory notes, including accrued interest, by $11.0 million and restructure the remaining $70.1 million of debt into the $35.0 million note that is convertible into shares of the Company’s common stock at $2.50 per share (the “Mann Group convertible note”) and the 3) Reduce the 5.75% Convertible Senior Subordinated Exchange Notes due 2021 (the “2021 notes”) by $8.5 million and restructure the remaining $10.2 million to the $2.6 million due June 2020 (the “June 2020 note”), $2.6 million due December 2020 (the “December 2020 note”, and together with the June 2020 note, the “2020 notes”), and the $5.0 million 5.75% Convertible Senior Subordinated Exchange Notes due November 2024 (the “2024 convertible notes”) which are convertible into shares of our common stock at $3.00 per share. The Company’s capital resources may not be sufficient to continue to meet its current and anticipated obligations over the next twelve months if the Company cannot increase its operating cash inflows by growing its prescription and revenue base and/or obtain access to the remaining $35.0 million borrowings that may become available under its MidCap Credit Facility. In the event these capital resources are not sufficient, the Company may need to raise additional capital by selling equity or debt securities, entering into strategic business collaboration agreements with other companies, seeking other funding facilities or licensing arrangements, selling assets or by other means. However, the Company cannot provide assurances that additional capital will be available on acceptable terms or at all. If the Company is unable to meet its current and anticipated obligations over the next twelve months through its existing capital resources, or obtain new sources of capital when needed, the Company may have to delay, reduce the scope of its manufacturing operations, reduce or eliminate one or more of its development programs, and/or make significant changes to its operating plan. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Principles of Consolidation	Principles of Consolidation — The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. Intercompany balances and transactions have been eliminated. Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported Consolidated Balance Sheets or Statements of Operations. An adjustment has been made to the Consolidated Statements of Cash Flows for the fiscal year ended December 31, 2018 to separately identify the disclosures of non-cash investing and financing activities related to the payment of facility obligation through common stock issuance and senior convertible notes through common stock issuance. This change in classification does not affect previously reported cash flows from operating, investing or financing activities. In addition, an adjustment has been made to reclassify certain immaterial amounts of professional fees to other accrued expenses within the table of accrued expenses in Note 5 — Accrued Expenses and Other Current Liabilities as of December 31, 2018 for consistency with the current year presentation.
Segment Information	Segment Information — Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. To date, the Company has viewed its operations and manages its business as one segment operating in the United States of America.
Revenue Recognition	Revenue Recognition — The Company adopted Accounting Standards Codification (“ASC”) Topic 606 - Revenue from Contracts with Customers (“the new revenue guidance”), on January 1, 2018. Under Topic 606, the Company recognizes revenue when its customers obtain control of promised goods or services, in an amount that reflects the consideration which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of Topic 606, the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to arrangements that meet the definition of a contract under Topic 606, including when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company has two types of contracts with customers: (i) contracts for commercial product sales with wholesale distributors and specialty pharmacies and (ii) collaboration arrangements.
Revenue Recognition - Net Revenue - Commercial Product Sales	Revenue Recognition – Net Revenue – Commercial Product Sales – The Company sells Afrezza to a limited number of wholesale distributors and specialty pharmacies in the U.S. (collectively, its “Customers”). Wholesale distributors subsequently resell the Company’s products to retail pharmacies and certain medical centers or hospitals. Specialty pharmacies sell directly to patients. In addition to distribution agreements with Customers, the Company enters into arrangements with payors that provide for government mandated and/or privately negotiated rebates, chargebacks, and discounts with respect to the purchase of the Company’s products. The Company recognizes revenue on product sales when the Customer obtains control of the Company's product, which occurs at delivery for wholesale distributors and at shipment for specialty pharmacies. Product revenues are recorded net of applicable reserves for variable consideration, including discounts and allowances. Free Goods Program – From time to time, the Company offers programs to potential new patients that allow them to obtain free goods (prescription fills) from a pharmacy. On a net basis, it is not probable that the Company will receive the consideration from these products. Therefore, the Company excludes such amounts from both gross and net revenue. The cost of product associated with the free goods program is included in cost of goods sold. Reserves for Variable Consideration — Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. Components of variable consideration include trade discounts and allowances, product returns, provider chargebacks and discounts, government rebates, payor rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its Customers, payors, and other indirect customers relating to the Company’s sale of its products. These reserves, as detailed below, are based on the amounts earned, or to be claimed on the related sales, and result in a reduction of accounts receivable or establishment of a current liability. Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted in accordance with the expected value method in Topic 606 for relevant factors such as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reduce recognized revenue to the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the respective underlying contracts. The amount of variable consideration which is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. The Company’s analysis also contemplates application of the constraint in accordance with the guidance, under which it determined a material reversal of revenue would not occur in a future period for the estimates detailed below as of December 31, 2019 and, therefore, the transaction price was not reduced further during the year ended December 31, 2019. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company will adjust these estimates, which would affect net revenue – commercial product sales and earnings in the period such variances become known. Trade Discounts and Allowances — The Company generally provides Customers with discounts which include incentives, such as prompt pay discounts, that are explicitly stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, the Company compensates (through trade discounts and allowances) its Customers for sales order management, data, and distribution services. However, the Company has determined such services received to date are not distinct from the Company’s sale of products to the Customer and, therefore, these payments have been recorded as a reduction of revenue and as a reduction to accounts receivable, net. Product Returns —Consistent with industry practice, the Company generally offers Customers a right of return for unopened product that has been purchased from the Company for a period beginning six months prior to and ending 12 months after its expiration date, which lapses upon shipment to a patient. The Company estimates the amount of its product sales that may be returned by its Customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized, as well as reductions to accounts receivable, net. The Company currently estimates product returns using available industry data and its own sales information, including its visibility into the inventory remaining in the distribution channel. The Company’s current return reserve percentage is estimated to be in the single digits. Provider Chargebacks and Discounts — Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase the product from the Company. Customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is recorded in accrued expenses and other current liabilities. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by Customers, and the Company generally issues credits for such amounts within a few weeks of the Customer’s notification to the Company of the resale. Reserves for chargebacks consist of credits that the Company expects to issue for units that remain in the distribution channel inventories at each reporting period-end that the Company expects will be sold to qualified healthcare providers, and chargebacks that Customers have claimed, but for which the Company has not yet issued a credit. Government Rebates — The Company is subject to discount obligations under Medicare and state Medicaid programs. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other current liabilities. For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The Company’s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel inventories at the end of each reporting period. Payor Rebates — The Company contracts with certain private payor organizations, primarily insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of its products. The Company estimates these rebates and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other current liabilities. Other Incentives — Other incentives which the Company offers include voluntary patient support programs, such as the Company's co-pay assistance program, which are intended to provide financial assistance to qualified commercially-insured patients with prescription drug co-payments required by payors. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with the product that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period. The adjustments are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other current liabilities.
Revenue Recognition- Net Revenue - Collaborations and Services	Revenue Recognition — Revenue — Collaborations and Services — The Company enters into licensing or research agreements under which the Company licenses certain rights to its product candidates to third parties or conducting research services to third parties. The terms of these arrangements may include, but are not limited to payment to the Company of one or more of the following: up-front license fees; development, regulatory, and commercial milestone payments; payments for manufacturing commercial and clinical supply services the Company provides; and royalties on net sales of licensed products and sublicenses of the rights. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment such as determining the performance obligation in the contract and determining the stand-alone selling price for each performance obligation identified in the contract. If an arrangement has multiple performance obligations, the allocation of the transaction price is determined from observable market inputs, and the Company uses key assumptions to determine the stand-alone selling price, which may include development timelines, reimbursement rates for personnel costs, discount rates, and probabilities of technical and regulatory success. Revenue is recognized based on the measurement of progress as the performance obligation is satisfied and consideration received that does not meet the requirements to satisfy the revenue recognition criteria is recorded as deferred revenue. Current deferred revenue consists of amounts that are expected to be recognized as revenue in the next 12 months. For further information see Note 8 Collaboration and Licensing Agreements. The Company recognizes upfront license payments as revenue upon delivery of the license only if the license is determined to be a separate unit of accounting from the other undelivered performance obligations. The undelivered performance obligations typically include manufacturing or development services or research and/or steering committee services. If the license is not considered as a distinct performance obligation, then the license and other undelivered performance obligations would be evaluated to determine if such should be accounted for as a single unit of accounting. If concluded to be a single performance obligation, the transaction price for the single performance obligation is recognized as revenue over the estimated period of when the performance obligation is satisfied. Whenever the Company determines that an arrangement should be accounted for over time, the Company determines the period over which the performance obligations will be performed, and revenue will be recognized over the period the Company is expected to complete its performance obligations. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations under an arrangement. The Company’s collaboration agreements typically entitle the Company to additional payments upon the achievement of development, regulatory and sales milestones. If the achievement of a milestone is considered probable at the inception of the collaboration, the related milestone payment is included with other collaboration consideration, such as upfront fees and research funding, in the Company’s revenue calculation. If these milestones are not considered probable at the inception of the collaboration, the milestones will typically be recognized in one of two ways depending on the timing of when the milestone is achieved. If the milestone is improbable at inception and subsequently deemed probable of achievement, such will be added to the transaction price, resulting in a cumulative adjustment to revenue. If the milestone is achieved after the performance period has completed and all performance obligations have been delivered, the Company will recognize the milestone payment as revenue in its entirety in the period the milestone was achieved. The Company’s collaborative agreements, for accounting purposes, represent contracts with customers and therefore are not subject to accounting literature on collaborative agreements. The Company grants licenses to its intellectual property, supplies raw materials or finished goods and provides research and development services, all of which are outputs of the Company’s ongoing activities, in exchange for consideration. The Company does not develop assets jointly with collaboration partners, and does not share in significant risks of their development or commercialization activities. Accordingly, the Company concluded that its collaborative agreements must be accounted for pursuant to Topic 606, Revenue from Contracts with Customers. For collaboration agreements that allow collaboration partners to select additional optioned products or services, the Company evaluates whether such options contain material rights (i.e., have exercise prices that are discounted compared to what the Company would charge for a similar product or service to a new collaboration partner). The exercise price of these options includes a combination of licensing fees, event-based milestone payments and royalties. When these amounts in aggregate are not offered at a discount that exceeds discounts available to other customers, the Company concludes the option does not contain a material right, and therefore is not included in the transaction price at contract inception. Rather, the Company evaluates grants of additional licensing rights upon option exercises to determine whether such should be accounted for as separate contracts. The Company concluded there is no material right in these options. The Company follows detailed accounting guidance in measuring revenue and certain judgments affect the application of its revenue policy. For example, in connection with its existing collaboration agreements, the Company has recorded on its consolidated balance sheets short-term and long-term deferred revenue based on its best estimate of when such revenue will be recognized. Short-term deferred revenue consists of amounts that are expected to be recognized as revenue in the next 12 months. Amounts that the Company expects will not be recognized within the next 12 months are classified as long-term deferred revenue. However, this estimate is based on the Company’s current project development plan and, if the development plan should change in the future, the Company may recognize a different amount of deferred revenue over the next 12-month period. The activity related to deferred revenue and the related revenue recognized for collaborations and services is as follows (in thousands): December 31, 2019 2018 Deferred revenue: Beginning balance $ 47,565 $ 750 Upfront and milestone payments 25,000 55,000 Pass through payments 6,016 2,398 Revenue — collaborations and services (37,734 ) (10,583 ) Ending balance $ 40,847 $ 47,565
Milestone Payments	Milestone Payments — At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the customer, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as, or when, the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company will re-evaluate the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration, other revenue, and earnings in the period of adjustment.
Cost of Goods Sold	Cost of Goods Sold — Cost of goods sold includes material, labor costs and manufacturing overhead. Cost of goods sold also includes a significant component of current period manufacturing costs in excess of costs capitalized into inventory (excess capacity costs). These costs, in addition to the impact of the annual revaluation of inventory to standard costs and write-offs of inventory are recorded as expenses in the period in which they are incurred, rather than as a portion of inventory costs. All insulin inventory on hand and the full purchase commitment contract to purchase future insulin was written off as of the end of 2015. Therefore, cost of goods sold excludes the cost of insulin purchased under our Insulin Supply Agreement, except for the contract amendment fees of approximately $2.8 million and $2.0 million for the years ended December 31, 2019 and 2018, respectively (see Note 13 – Commitments and Contingencies).
Cash and Cash Equivalents and Restricted Cash	Cash and Cash Equivalents – The Company considers all highly liquid investments with original or remaining maturities of 90 days or less at the time of purchase, that are readily convertible into cash to be cash equivalents. As of December 31, 2019 and 2018, cash equivalents were comprised of money market accounts with maturities less than 90 days from the date of purchase. The Company records restricted cash when cash and cash equivalents are restricted as to withdrawal or usage. The Company presents amounts of restricted cash that will be available for use within 12 months of the reporting date as restricted cash in current assets. Restricted cash amounts that will not be available for use in the Company’s operations within 12 months of the reporting date are presented as restricted cash in long term assets. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported on the consolidated balance sheets that sum to amounts reported on the consolidated statement of cash flows (in thousands): December 31, 2019 2018 Cash and cash equivalents $ 29,906 $ 71,157 Restricted cash 316 527 Total cash, cash equivalents, and restricted cash $ 30,222 $ 71,684
Short-term Investments	Short-term Investments The Company’s short-term investments consist of U.S. Treasury securities stated at amortized cost which the Company intends to hold until maturity. Those with maturities less than 12 months are included in short-term investments and any investments with maturities in excess of twelve months are included in long-term investments in our consolidated balance sheets. The Company did not record any material gains or losses on these securities during the years ended December 31, 2019 and 2018.
Concentration of Credit Risk	Concentration of Credit Risk — Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents and short-term investments. Cash and cash equivalents are held in high credit quality institutions. Cash equivalents consist of interest-bearing money market accounts and U.S. Treasury securities, which are regularly monitored by management. Short-term investments consist of U.S. Treasury securities with a maximum maturity of twelve months.
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts — Accounts receivable are recorded at the invoiced amount and are not interest bearing. Accounts receivable are presented net of an allowance for doubtful accounts if there are estimated losses resulting from the inability of its customers to make required payments. The Company makes ongoing assumptions relating to the collectability of its accounts receivable in its calculation of the allowance for doubtful accounts. Accounts receivable are also presented net of an allowance for product returns and trade discounts and allowances because the Company’s customers have the right of setoff for these amounts against the related accounts receivable. Accounts receivable, net consists of the following (in thousands): December 31, 2019 2018 Accounts Receivable, gross $ 6,925 $ 5,198 Wholesaler distribution fees and prompt pay discounts (1,767 ) (868 ) Reserve for returns (1,645 ) (313 ) Accounts receivable, net $ 3,513 $ 4,017 As of December 31, 2019 and December 31, 2018, the allowance for doubtful accounts was de minimis. As of December 31, 2019 and December 31, 2018, the Company had three wholesale distributors representing approximately 96% and 89% of sales, respectively.
Pre Launch Inventory	Pre-Launch Inventory — An improvement to the manufacturing process for the Company’s primary excipient FDKP was demonstrated to be viable and management expects to realize an economic benefit in the future as a result of such process improvement. Accordingly, the Company is required to assess whether to capitalize inventory costs related to such excipient prior to regulatory approval of the new supplier and the improved manufacturing process. In doing so, management must consider a number of factors in order to determine the amount of inventory to be capitalized, including the historical experience of achieving regulatory approvals for the Company’s manufacturing process, feedback from regulatory agencies on the changes being effected and the amount of inventory that is likely to be used in commercial production. The shelf life of the excipient will be determined as part of the regulatory approval process; in the interim, the Company must assess the available stability data to determine whether there is likely to be adequate shelf life to support anticipated future sales occurring beyond the expected approval date of the new raw material. If management is aware of any specific material risks or contingencies other than the normal regulatory review and approval process, or if the criteria for capitalizing inventory produced prior to regulatory approval are otherwise not met, the Company would not capitalize such inventory costs, choosing instead to recognize such costs as a research and development expense in the period incurred.
Inventories	Inventories — Inventories are stated at the lower of cost or net realizable value. The Company determines the cost of inventory using the first-in, first-out, or FIFO, method. The Company capitalizes inventory costs associated with the Company’s products based on management’s judgment that future economic benefits are expected to be realized; otherwise, such costs are expensed as incurred as cost of goods sold. The Company periodically analyzes its inventory levels to identify inventory that may expire or has a cost basis in excess of its estimated realizable value and writes down such inventories, as appropriate. In addition, the Company’s products are subject to strict quality control and monitoring which the Company performs throughout the manufacturing process. If certain batches or units of product no longer meet quality specifications or may become obsolete or are forecasted to become obsolete due to expiration, the Company will record a charge to write down such unmarketable inventory to its estimated net realizable value. The Company analyzes its inventory levels to identify inventory that may expire or has a cost basis in excess of its estimated realizable value. The Company performs an assessment of projected sales and evaluates the lower of cost or net realizable value and the potential excess inventory on hand at the end of each reporting period.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets — The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Assets are considered to be impaired if the carrying value may not be recoverable. If the Company believes an asset to be impaired, the impairment recognized is the amount by which the carrying value of the asset exceeds the fair value of the asset. Fair value is determined using the market, income or cost approaches as appropriate for the asset. Any write-downs are treated as permanent reductions in the carrying amount of the asset and recognized as an operating loss. The Company recorded zero asset impairments for the years ended December 31, 2019 and 2018 (see Note 4 — Property and Equipment).
Recognized Loss on Purchase Commitments	Recognized Loss on Purchase Commitments — The Company assesses whether losses on long term purchase commitments should be accrued. Losses that are expected to arise from firm, non-cancellable, commitments for the future purchases are recognized unless recoverable. When making the assessment, the Company also considers whether it is able to renegotiate with its vendors. The recognized loss on purchase commitments is reduced as inventory items are received. If, subsequent to an accrual, a purchase commitment is successfully renegotiated, the gain is recognized in the Company’s consolidated statement of operations. The liability balance of the recognized loss on insulin purchase commitments as of December 31, 2019 and 2018 was $92.0 million and $98.3 million, respectively.
Milestone Rights Liability	Milestone Rights Liability — On July 1, 2013, in conjunction with the execution of the Facility Agreement, the Company issued Milestone Rights to the Milestone Purchasers. The Milestone Rights provide the Milestone Purchasers certain rights to receive payments of up to $90.0 million, of which $70.0 million remain payable as of December 31, 2019, upon the occurrence of specified strategic and sales milestones, including the achievement of specified net sales figures. The Company analyzed the Milestone Rights and determined that the Milestone Agreement does not meet the definition of a freestanding derivative. Since the Company has not elected to apply the fair value option to the Milestone Agreement, the Company recorded the Milestone Rights at their estimated initial fair value and accounted for the Milestone Rights as a liability. The initial fair value estimate of the Milestone Rights was calculated using the income approach in which the cash flows associated with the specified contractual payments were adjusted for both the expected timing and the probability of achieving the milestones and discounted to present value using a selected market discount rate. The expected timing and probability of achieving the milestones was developed with consideration given to both internal data, such as progress made to date and assessment of criteria required for achievement, and external data, such as market research studies. The discount rate was selected based on an estimation of required rate of returns for similar investment opportunities using available market data. The Milestone Rights liability will be remeasured as the specified milestone events are achieved. Specifically, as each milestone event is achieved, the portion of the initially recorded Milestone Rights liability that pertains to the milestone event being achieved, will be remeasured to the amount of the specified related milestone payment. The resulting change in the balance of the Milestone Rights liability due to remeasurement will be recorded in the Company’s consolidated statements of operations as interest expense. Furthermore, the Milestone Rights liability will be reduced upon the settlement of each milestone payment. As a result, each milestone payment would be effectively allocated between a reduction of the recorded Milestone Rights liability and an expense representing a return on a portion of the Milestone Rights liability paid to the investor for the achievement of the related milestone event (see Note 7 — Borrowings). As of December 31, 2019 and 2018, the remaining liability balance was $7.3 million and $8.9 million, respectively.
Fair Value of Financial Instruments	Fair Value of Financial Instruments —The Company applies various valuation approaches in determining the fair value of its financial assets and liabilities within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is broken down into three levels based on the source of inputs as follows: Level 1 — Quoted prices for identical instruments in active markets. Level 2 — Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable. Level 3 — Significant inputs to the valuation model are unobservable.
Income Taxes	Income Taxes — The provisions for federal, foreign, state and local income taxes are calculated on pre-tax income based on current tax law and include the cumulative effect of any changes in tax rates from those used previously in determining deferred tax assets and liabilities. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. A valuation allowance is recorded to reduce net deferred income tax assets to amounts that are more likely than not to be realized. Income tax positions are considered for uncertainty. The Company believes that its income tax filing positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position. Therefore, no liabilities for uncertain income tax positions have been recorded. If a tax position does not meet the minimum statutory threshold to avoid payment of penalties, the Company recognizes an expense for the amount of the penalty in the period the tax position is claimed in the tax return of the Company. The Company recognizes interest accrued related to unrecognized tax benefits in income tax expense, if any. Penalties, if probable and reasonably estimable, are recognized as a component of income tax expense.
Contingencies	Contingencies — The Company records a loss contingency for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. These accruals represent management’s best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. Significant judgment is required in both the determination of probability and the determination as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation and may revise its estimates.
Stock-Based Compensation	Stock-Based Compensation — Share-based payments to employees, including grants of stock options, restricted stock units, performance-based awards and the compensatory elements of employee stock purchase plans, are recognized in the consolidated statements of operations based upon the fair value of the awards at the grant date. The Company uses the Black-Scholes option valuation model to estimate the grant date fair value of employee stock options and the compensatory elements of employee stock purchase plans. Restricted stock units are valued based on the market price on the grant date. The Company evaluates stock awards with performance conditions as to the probability that the performance conditions will be met and estimates the date at which the performance conditions will be met in order to properly recognize stock-based compensation expense over the requisite service period.
Clinical Trial Expenses	Clinical Trial Expenses — Clinical trial expenses, which are primarily reflected in research and development expenses in the accompanying consolidated statements of operations, result from obligations under contracts with vendors, consultants and clinical site agreements in connection with conducting clinical trials.
Net Income or (Loss) Per Share of Common Stock	Net Income (Loss) Per Share of Common Stock — Basic net income or loss per share excludes dilution for potentially dilutive securities and is computed by dividing net income or loss by the weighted average number of common shares outstanding during the period. Diluted net income or loss per share reflects the potential dilution under the treasury method that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. For periods where the Company has presented a net loss, potentially dilutive securities are excluded from the computation of diluted net loss per share as they would be anti-dilutive.
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards — Leases —The Company adopted Accounting Standards Codification (“ASC”) Topic 842 – Leases (“ASC 842”) on January 1, 2019. Under ASC 842, the Company is required to recognize the assets and liabilities that arise from most operating leases on the balance sheet and disclose qualitative and quantitative information about its leasing arrangements. Upon adoption of ASC 842, the Company recognized a lease liability to make lease payments and a right-of-use-asset representing its right to use the underlying asset for the applicable lease term using the optional transition method. In doing so, the Company elected the package of three practical expedients permitted under the transition guidance within the new standard, which among other things, allowed the Company to carry forward the historical lease classification. The Company also elected the practical expedient that permits not separating lease and non-lease components for all classes of underlying assets. For short-term leases, the Company has elected not to apply the recognition requirements of this guidance. The Company did not elect to use the hindsight practical expedient. Upon the adoption as of January 1, 2019, the impact on total assets and total liabilities was an increase of $5.2 million. The standard did not materially impact net earnings and had no impact on cash flow. See Note 13 — Commitments and Contingencies for further information related to leases. In July 2017, the FASB issued ASU No. 2017-11, Earnings per Share (Topic 260) and Derivatives and Hedging (Topic 815)
Recently Issued Accounting Standards	Recently Issued Accounting Standards — From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s consolidated financial position or results of operations upon adoption. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740) In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangements (Topic 808)

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Schedule of Deferred Revenue Related to Revenue Recognized for Collaborations and Services	The activity related to deferred revenue and the related revenue recognized for collaborations and services is as follows (in thousands): December 31, 2019 2018 Deferred revenue: Beginning balance $ 47,565 $ 750 Upfront and milestone payments 25,000 55,000 Pass through payments 6,016 2,398 Revenue — collaborations and services (37,734 ) (10,583 ) Ending balance $ 40,847 $ 47,565
Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash	The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported on the consolidated balance sheets that sum to amounts reported on the consolidated statement of cash flows (in thousands): December 31, 2019 2018 Cash and cash equivalents $ 29,906 $ 71,157 Restricted cash 316 527 Total cash, cash equivalents, and restricted cash $ 30,222 $ 71,684
Schedule of Accounts Receivable, Net	Accounts receivable, net consists of the following (in thousands): December 31, 2019 2018 Accounts Receivable, gross $ 6,925 $ 5,198 Wholesaler distribution fees and prompt pay discounts (1,767 ) (868 ) Reserve for returns (1,645 ) (313 ) Accounts receivable, net $ 3,513 $ 4,017

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2019
Inventory Disclosure [Abstract]
Components of Inventory	Inventories consist of the following (in thousands): December 31, 2019 2018 Raw materials $ 1,751 $ 1,337 Work-in-process 1,432 1,605 Finished goods 972 655 Total inventory $ 4,155 $ 3,597

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2019
Property Plant And Equipment [Abstract]
Property and Equipment, Net	Property and equipment consist of the following (in thousands): Estimated Useful December 31, Life (Years) 2019 2018 Land — $ 875 $ 875 Buildings 39-40 17,389 17,389 Building improvements 5-40 37,543 34,967 Machinery and equipment 3-15 54,982 61,217 Furniture, fixtures and office equipment 5-10 3,005 2,954 Computer equipment and software 3 8,234 8,355 Construction in progress — 114 342 122,142 126,099 Less accumulated depreciation (95,364 ) (100,497 ) Total property and equipment, net $ 26,778 $ 25,602

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2019
Payables And Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities are comprised of the following (in thousands): December 31, 2019 2018 Salary and related expenses $ 8,835 $ 8,110 Discounts and allowances for commercial product sales 3,162 2,656 Deferred lease liability 1,433 257 Professional fees 620 457 Accrued interest 409 492 Sales and marketing services 147 88 Other 1,298 1,319 Current portion of milestone rights liability — 1,643 Accrued expenses and other current liabilities $ 15,904 $ 15,022

Borrowings (Tables)

Borrowings (Tables)	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Summary of Carrying Amount of Borrowings	Carrying amount of borrowings consist of the following (in thousands): December 31, 2019 2018 Mann Group promissory notes $ 70,020 $ 72,089 MidCap Credit Facility 38,851 — Senior notes 10,028 19,099 Deerfield Credit Facility — 11,298 Total debt — net carrying amount $ 118,899 $ 102,486
Schedule of Line of Credit Facility Debt and Key Terms	During the year ended December 31, 2019, the Company discharged its obligations under the Deerfield Credit Facility, entered into the MidCap Credit Facility and restructured the obligations owed to its other lenders. The following table provides a summary of the Company’s debt and key terms: December 31, 2019 2018 Amount Due Annual interest rate Maturity date Conversion price Amount Due Annual interest rate Maturity date Conversion price Mann Group convertible note $35.0 million (plus $1.0 million accrued interest paid-in-kind) 7.00% November 2024 $2.50 per share $71.5 million (plus $6.8 million accrued interest paid-in-kind) 5.84 % July 2021 $4.00 per share Mann Group non- convertible note $35.1 million (plus $1.0 million accrued interest paid-in-kind) 7.00% November 2024 N/A — — — — MidCap Credit Facility $40.0 million one-month LIBOR (2% floor) plus 6.75% August 2024 N/A — — — — 2024 convertible notes $5.0 million 5.75% November 2024 $3.00 per share $18.7 million 5.75 % October 2021 $5.15 per share June 2020 note $2.6 million — June 2020 N/A — — — — December 2020 note $2.6 million — December 2020 N/A — — — — Deerfield Credit Facility — — — — $4.0 million 9.75 % July 2019 N/A — — — — $5.0 million 9.75 % August 2019 N/A — — — — $2.5 million 8.75 % May 2019 N/A
Schedule of Maturities of Our Borrowings	The maturities of our borrowings as of December 31, 2019 are as follows (in thousands): Amounts 2020 $ 5,262 2021 4,444 2022 13,333 2023 13,333 2024 83,940 Thereafter — Total principal payments 120,312 Unamortized discount (539 ) Debt issuance costs (874 ) Total debt $ 118,899
Schedule of Amortization of Premium and Accretion of Debt Issuance Costs	Amortization of the premium and accretion of debt issuance costs related to all borrowings for the years ended December 31, 2019 and 2018 are as follows (in thousands): Year Ended December 31, 2019 2018 Amortization of debt premium $ (1,049 ) $ (339 ) Amortization of debt discount 295 1,155 Accretion expense — debt issuance cost (111 ) (69 )

Collaboration and Licensing A_2

Collaboration and Licensing Arrangements (Tables)	12 Months Ended
	Dec. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Schedule of Revenue from Collaboration and Services	Revenue from collaborations and services for the years ended December 31, 2019 and 2018 are as follows (in thousands): Year Ended December 31, 2019 2018 UT License Agreement $ 31,229 $ 6,386 UT Research Agreement 6,032 3,758 Receptor CLA 250 341 Cipla distribution agreement 148 98 Biomm distribution agreement 75 — Total revenue from collaborations and services $ 37,734 $ 10,583

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurement of Debt Instruments Based on Discounted Cash Flow Model and Sensitive to Change in Yield	The fair value measurement of debt instruments is based on a discounted cash flow model and is sensitive to the change in yield (Level 3 in the fair value hierarchy): Hypothetical Change in Yield Hypothetical Change in Notes Payable Yield % Change Hypothetical Yield FV of Notes FV $ Change % Change (in millions) Mann Group promissory notes: (with conversion feature) 29.0 % 2 % 31.0 % $ 46.2 $ 44.1 $ (2.1 ) -4.5 % 29.0 % -2 % 27.0 % $ 46.2 $ 48.5 $ 2.3 5.0 % 29.0 % 4 % 33.0 % $ 46.2 $ 42.2 $ (4.0 ) -8.7 % 29.0 % -4 % 25.0 % $ 46.2 $ 51.0 $ 4.8 10.4 % Senior notes: (with conversion feature) 29.0 % 2 % 31.0 % $ 8.0 $ 7.8 $ (0.2 ) -2.5 % 29.0 % -2 % 27.0 % $ 8.0 $ 8.2 $ 0.2 2.5 % 29.0 % 4 % 33.0 % $ 8.0 $ 7.6 $ (0.4 ) -5.0 % 29.0 % -4 % 25.0 % $ 8.0 $ 8.4 $ 0.4 5.0 % MidCap Credit Facility 11.5 % 1 % 12.5 % $ 40.0 $ 39.0 $ (1.0 ) -2.5 % 11.5 % -1 % 10.5 % $ 40.0 $ 41.0 $ 1.0 2.5 % 11.5 % 2 % 13.5 % $ 40.0 $ 38.1 $ (1.9 ) -4.8 % 11.5 % -2 % 9.5 % $ 40.0 $ 42.1 $ 2.1 5.3 %
Fair Value of Financial Instruments	The following tables set forth the fair value of the Company’s financial instruments as of December 31, 2019 and 2018 (in millions): December 31, 2019 Fair Value Carrying Amount Significant Unobservable Inputs (Level 3) Total Fair Value Financial liabilities: MidCap Credit Facility $ 38.9 $ 40.0 $ 40.0 2024 convertible notes 5.0 3.7 3.7 June 2020 note 2.5 2.3 2.3 December 2020 note 2.5 2.0 2.0 Mann Group promissory notes 70.0 46.2 46.2 Milestone Rights 7.3 16.4 16.4 Total financial liabilities $ 126.2 $ 110.6 $ 110.6 December 31, 2018 Fair Value Carrying Value Significant Unobservable Inputs (Level 3) Total Fair Value Financial liabilities: Deerfield Credit Facility $ 11.3 $ 11.4 $ 11.4 Senior convertible notes 19.1 17.5 17.5 Mann Group promissory notes 72.1 55.0 55.0 Milestone Rights 8.9 18.1 18.1 Total financial liabilities $ 111.4 $ 102.0 $ 102.0

Earnings Per Common Share ("E_2

Earnings Per Common Share ("EPS") (Tables)	12 Months Ended
	Dec. 31, 2019
Earnings Per Share [Abstract]
Components of Basic and Diluted EPS Computations	The following tables summarize the components of the basic and diluted EPS computations (in thousands, except per share amounts): Year Ended December 31, 2019 2018 EPS — basic and diluted: Net loss (numerator) $ (51,903 ) $ (86,975 ) Weighted average common shares (denominator) 195,584 144,136 Net loss per share $ (0.27 ) $ (0.60 )
Potential Dilutive Securities Outstanding that are Considered Antidilutive	Potentially dilutive securities outstanding that are considered antidilutive are summarized as follows (in shares): Year Ended December 31, 2019 2018 Exercise of common stock options 14,135,681 10,976,118 Conversion of convertible notes payable to former related party into common stock 14,000,000 21,909,541 Exercise of warrants associated with public offering 7,250,000 26,666,667 Exercise of warrants associated with Midcap Credit Facility 1,171,614 — Conversion of convertible notes into common stock 1,666,667 3,629,627 Vesting of restricted stock units 1,057,047 691,266 Employee stock purchase plan 369,979 307,395 Exercise of common stock warrants 31,851 31,851 Exercise of warrants associated with direct placement — 14,000,000 Total 39,682,839 78,212,465

Stock Award Plans (Tables)

Stock Award Plans (Tables)	12 Months Ended
	Dec. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Based Award Plans	The following table summarizes information about the Company’s stock-based award plans as of December 31, 2019: Outstanding Options Outstanding Restricted Stock Units Shares Available for Future Issuance 2004 Equity Incentive Plan 451,149 — — 2013 Equity Incentive Plan 4,714,169 393,309 — 2018 Equity Incentive Plan 8,934,586 663,738 4,710,565 2004 Non-Employee Directors’ Stock Option Plan 35,777 — — Total 14,135,681 1,057,047 4,710,565
Stock Based Compensation Expense Recognized in Accompanying Consolidated Statements of Operations by Category	Total stock-based compensation expense recognized in the accompanying consolidated statements of operations is included in the following categories (in thousands): Year Ended December 31, 2019 2018 Cost of goods sold $ 601 $ 379 Research and development 356 1,203 Selling, general and administrative 4,508 5,275 Cost of revenue — collaborations and services 738 — Total $ 6,203 $ 6,857
Assumptions Used to Calculate Fair Value of Employee Stock Options	The Company calculated the fair value of employee stock options granted during the years ended December 31, 2019 and 2018 using the following assumptions: Year Ended December 31, 2019 2018 Risk-free interest rate 1.52% — 2.51% 2.63% — 3.11% Expected lives 6.20 — 9.37 years 5.90 — 7.19 years Volatility 93.05% — 94.25% 92.68% — 93.62% Dividends — —
Summary of Stock Options Outstanding	The following table summarizes information about stock options outstanding: Number of Shares Weighted Average Exercise Price per Share Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value ($000) Outstanding at January 1, 2019 10,976,118 $ 5.75 7.83 $ — Granted 5,613,253 1.32 Exercised (67,461 ) 1.10 Forfeited (1,395,644 ) 2.25 Expired (990,585 ) 17.07 Outstanding at December 31, 2019 14,135,681 $ 3.09 7.84 $ 182 Exercisable at December 31, 2019 4,554,661 $ 6.20 6.00 $ 86
Summary of Restricted Stock Unit Activity	A summary of restricted stock unit activity for the year ended December 31, 2019 is presented below: Number of Shares Weighted Average Grant Date Fair Value per Share Outstanding at January 1, 2019 691,266 $ 3.72 Granted 1,293,690 1.42 Vested (804,105 ) 2.33 Forfeited (123,804 ) 2.06 Outstanding at December 31, 2019 1,057,047 2.16

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2019
Commitments And Contingencies Disclosure [Abstract]
Annual Purchase Requirements under Amended Contract	In August 2019, the Company and Amphastar amended the Insulin Supply Agreement to extend the term to 2026 and to restructure the annual purchase commitments. The annual purchase requirements under the amended contract are as follows: Minimum Commitment 2020 € 6.6 million 2021 € 6.6 million 2022 € 8.5 million 2023 € 10.8 million 2024 € 14.6 million 2025 € 15.5 million 2026 € 19.4 million
Schedule of Future Minimum Office And Vehicle Lease Payments	Future minimum office and vehicle lease payments as of December 31, 2019 and 2018 were as follows: December 31, 2019 2018 2019 $ — $ 1,595,421 2020 1,470,217 1,623,835 2021 1,499,484 1,653,101 2022 1,241,089 1,305,096 2023 87,957 87,957 Total $ 4,298,747 $ 6,265,410 The 2018 amounts above are inclusive of office and vehicle lease payments in order to conform to the current year’s presentation.

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Loss from Continuing Operations Before Provision for Income Tax	Loss from continuing operations before provision for income tax for the Company’s domestic and international operations was as follows (in thousands): Year Ended December 31, 2019 2018 United States $ (51,044 ) $ (84,207 ) Foreign (859 ) (2,528 ) Loss before provision for income taxes $ (51,903 ) $ (86,735 )
Provision for Income Taxes	The provision for income taxes consists of the following (in thousands): Year Ended December 31, 2019 2018 Current U.S. federal $ — $ — U.S. state — — Non-U.S. — 240 Total current — 240 Deferred U.S. federal (8,551 ) (9,164 ) U.S. state 3,299 (1,903 ) Non-U.S. — — Total deferred (5,252 ) (11,067 ) Valuation allowance 5,252 11,067 Total $ — $ 240
Components of Net Deferred Tax Assets	Components of the net deferred tax assets as of December 31, 2019 and 2018, are as follows (in thousands): December 31, 2019 2018 Deferred tax assets: Net operating loss carryforwards $ 531,970 $ 524,377 Research and development credits 80,488 81,583 Capitalized research 44 557 Milestone Rights 1,528 3,521 Accrued expenses 1,951 1,156 Loss on purchase commitment 22,167 23,194 Non-qualified stock option expense 3,128 2,551 Capitalized patent costs 4,964 5,090 Other 147 669 Lease liability 827 — Interest expense limitation 1,167 — Depreciation 21,132 22,560 Deferred Product Revenue & Costs 2,062 107 Total net deferred tax assets 671,575 665,365 Valuation allowance (670,617 ) (665,365 ) Net deferred tax assets $ 958 $ — Deferred tax liabilities: Right of use asset $ (751 ) $ — Other prepaids (207 ) — Total deferred tax liabilities (958 ) — Net deferred tax assets $ — $ —
Effective Income Tax Rate	The Company’s effective income tax rate differs from the statutory federal income tax rate as follows for the years ended December 31, 2019 and 2018: Year Ended December 31, 2019 2018 Federal tax benefit rate 21.0 % 21.0 % Permanent items (3.3 ) 1.0 Tax law changes (2.7 ) (0.7 ) Stock based compensation (0.9 ) (6.5 ) Tax attribute expirations (4.0 ) (1.6 ) Foreign withholding tax — (0.3 ) Valuation allowance (10.1 ) (13.2 ) Effective income tax rate 0.0 % -0.3 %

Selected quarterly financial _2

Selected quarterly financial data (unaudited) (Tables)	12 Months Ended
	Dec. 31, 2019
Quarterly Financial Information Disclosure [Abstract]
Selected Quarterly Financial Data	Summarized quarterly financial data for the years ended December 31, 2019 and 2018, are set forth in the following tables: March 31 June 30 September 30 December 31 (In thousands, except per share data) 2019 Net revenues $ 17,448 $ 15,002 $ 14,595 $ 15,993 Net loss $ (14,883 ) $ (12,387 ) $ (10,370 ) $ (14,263 ) Net loss per share — basic and diluted $ (0.08 ) $ (0.07 ) $ (0.05 ) $ (0.07 ) Weighted average common shares used to compute net loss per share — basic and diluted 187,434 188,054 199,906 206,689 2018 Net revenues $ 3,465 $ 3,893 $ 4,469 $ 16,031 Net loss $ (30,385 ) $ (22,675 ) $ (24,168 ) $ (9,747 ) Net loss per share — basic and diluted $ (0.25 ) $ (0.16 ) $ (0.16 ) $ (0.06 ) Weighted average common shares used to compute net loss per share — basic and diluted 120,911 140,054 153,597 161,397

Description of Business - Addit

Description of Business - Additional Information (Detail) - USD ($)	Aug. 06, 2019	Aug. 31, 2019	Dec. 31, 2019	Jun. 30, 2019	Dec. 31, 2018
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Accumulated deficit			$ (2,991,903,000)		$ (2,940,000,000)
Principal amount			120,300,000
Cash and cash equivalents			29,906,000		71,157,000
Short-term investments			19,978,000
Remaining debt amount			70,020,000		72,089,000
The Mann Group LLC
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Remaining debt amount				$ 70,100,000	72,100,000
Facility Financing Obligation | Deerfield
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Repayments of aggregate principal amount			5,000,000
Convertible Promissory Note | The Mann Group LLC
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Principal amount			35,000,000		$ 71,500,000
Repayments of debt			$ 11,000,000
Conversion price of shares			$ 2.50		$ 4
Senior notes, effective interest rate			7.00%		5.84%
Convertible Promissory Note | The Mann Group LLC | New Loan Arrangement
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Principal amount			$ 35,000,000
Conversion price of shares		$ 2.50	$ 2.50
Senior notes, effective interest rate		7.00%
Non-Convertible Promissory Note | The Mann Group LLC
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Principal amount			$ 35,100,000
Senior notes, effective interest rate			7.00%
Non-Convertible Promissory Note | The Mann Group LLC | New Loan Arrangement
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Principal amount			$ 35,100,000
Senior notes, effective interest rate		7.00%
2021 Notes
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Principal amount			10,200,000
Repayments of aggregate principal amount			$ 8,500,000
Reducing senior subordinated interest rate, percentage			5.75%
June 2020 Note
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Principal amount			$ 2,600,000
Maturity period, month and year			2020-06
December 2020 Note
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Principal amount			$ 2,600,000
Maturity period, month and year			2020-12
2024 Convertible Notes
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Principal amount			$ 5,000,000
Conversion price of shares			$ 3
Maturity period, month and year			2024-11
Senior notes, effective interest rate			5.75%
MidCap Credit Facility
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Principal amount			$ 40,000,000
Principal amount, credit facility		$ 75,000,000
Amount outstanding			40,000,000
Amount available under credit facility		35,000,000
Reducing senior subordinated interest rate, percentage	2.00%
MidCap Credit Facility | Tranche 2
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Amount available under credit facility		10,000,000
Debt instrument, minimum target net revenue		30,000,000
Minimum cash covenant	$ 15,000,000		15,000,000
MidCap Credit Facility | Tranche 3
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Amount available under credit facility		$ 25,000,000
Minimum cash covenant			$ 20,000,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Detail 1)	Dec. 31, 2019
Collaborations and services | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2020-01-01
Summary Of Significant Accounting Policies [Line Items]
Remaining performance obligation, Expected timing of satisfaction, period	12 months

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2019USD ($)Distributor	Dec. 31, 2018USD ($)Distributor	Jan. 01, 2019USD ($)	Jul. 01, 2013USD ($)
Summary Of Significant Accounting Policies [Line Items]
Number of wholesale distributors | Distributor	3	3
Percentage of sales from major wholesale distributors	96.00%	89.00%
Asset impairments	$ 0	$ 0
Liabilities for uncertain income tax positions	0	0
(“ASC”) Topic 842 – Leases
Summary Of Significant Accounting Policies [Line Items]
Increase in total assets and total liabilities			$ 5,200,000
Deerfield | Facility Financing Obligation
Summary Of Significant Accounting Policies [Line Items]
Remaining milestone rights liability	7,300,000	8,900,000
Milestone Rights Liability | Deerfield
Summary Of Significant Accounting Policies [Line Items]
Contingent liability remain payable	70,000,000
Cost of Goods Sold
Summary Of Significant Accounting Policies [Line Items]
Purchase commitments, amendment fees	2,800,000	2,000,000
Insulin
Summary Of Significant Accounting Policies [Line Items]
Loss on purchase commitments	$ 92,000,000	$ 98,300,000
Minimum | AFREZZA product sales
Summary Of Significant Accounting Policies [Line Items]
Sales return right following product expiration in months	6 months
Maximum | Milestone Rights Liability | Deerfield
Summary Of Significant Accounting Policies [Line Items]
Contingent liability for milestone payments				$ 90,000,000
Maximum | AFREZZA product sales
Summary Of Significant Accounting Policies [Line Items]
Sales return right following product expiration in months	12 months

Schedule of Deferred Revenue Re

Schedule of Deferred Revenue Related to Revenue Recognized for Collaborations and Services (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Revenue From Contract With Customer [Abstract]
Beginning balance	$ 47,565	$ 750
Upfront and milestone payments	25,000	55,000
Pass through payments	6,016	2,398
Revenue — collaborations and services	(37,734)	(10,583)
Ending balance	$ 40,847	$ 47,565

Schedule of Reconciliation of C

Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Cash and cash equivalents	$ 29,906	$ 71,157
Restricted cash	316	527
Total cash, cash equivalents, and restricted cash	$ 30,222	$ 71,684	$ 48,355

Schedule of Accounts Receivable

Schedule of Accounts Receivable, Net (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Receivables [Abstract]
Accounts Receivable, gross	$ 6,925	$ 5,198
Wholesaler distribution fees and prompt pay discounts	(1,767)	(868)
Reserve for returns	(1,645)	(313)
Accounts receivable, net	$ 3,513	$ 4,017

Components of Inventories (Deta

Components of Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw materials	$ 1,751	$ 1,337
Work-in-process	1,432	1,605
Finished goods	972	655
Total inventory	$ 4,155	$ 3,597

Inventories - Additional Inform

Inventories - Additional Information (Detail) - USD ($)	1 Months Ended	12 Months Ended
	Nov. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Inventory [Line Items]
Percentage of material received	2.00%
Write-down of inventory		$ 0	$ 2,212,000
Pre-launch Inventory
Inventory [Line Items]
Raw materials inventory		$ 800,000	$ 0

Property and Equipment, Net (De

Property and Equipment, Net (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Property Plant And Equipment [Line Items]
Property and equipment - gross	$ 122,142	$ 126,099
Less accumulated depreciation	(95,364)	(100,497)
Total property and equipment, net	26,778	25,602
Land
Property Plant And Equipment [Line Items]
Property and equipment - gross	875	875
Buildings
Property Plant And Equipment [Line Items]
Property and equipment - gross	$ 17,389	17,389
Buildings | Minimum
Property Plant And Equipment [Line Items]
Estimated Useful Life (Years)	39 years
Buildings | Maximum
Property Plant And Equipment [Line Items]
Estimated Useful Life (Years)	40 years
Building Improvements
Property Plant And Equipment [Line Items]
Property and equipment - gross	$ 37,543	34,967
Building Improvements | Minimum
Property Plant And Equipment [Line Items]
Estimated Useful Life (Years)	5 years
Building Improvements | Maximum
Property Plant And Equipment [Line Items]
Estimated Useful Life (Years)	40 years
Machinery and Equipment
Property Plant And Equipment [Line Items]
Property and equipment - gross	$ 54,982	61,217
Machinery and Equipment | Minimum
Property Plant And Equipment [Line Items]
Estimated Useful Life (Years)	3 years
Machinery and Equipment | Maximum
Property Plant And Equipment [Line Items]
Estimated Useful Life (Years)	15 years
Furniture, fixtures and office equipment
Property Plant And Equipment [Line Items]
Property and equipment - gross	$ 3,005	2,954
Furniture, fixtures and office equipment | Minimum
Property Plant And Equipment [Line Items]
Estimated Useful Life (Years)	5 years
Furniture, fixtures and office equipment | Maximum
Property Plant And Equipment [Line Items]
Estimated Useful Life (Years)	10 years
Computer Equipment and Software
Property Plant And Equipment [Line Items]
Property and equipment - gross	$ 8,234	8,355
Estimated Useful Life (Years)	3 years
Construction in Progress
Property Plant And Equipment [Line Items]
Property and equipment - gross	$ 114	$ 342

Property and Equipment - Additi

Property and Equipment - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Property Plant And Equipment [Line Items]
Depreciation Expense	$ 1.6	$ 1.7
Furniture and Fixtures, Manufacturing Equipment and Laboratory Equipment
Property Plant And Equipment [Line Items]
Amount of divestiture of long-lived		$ 2.1
Manufacturing Equipment and Computer Hardware
Property Plant And Equipment [Line Items]
Amount of divestiture of long-lived	$ 6.7

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Accrued Expenses And Other Current Liabilities [Abstract]
Salary and related expenses	$ 8,835	$ 8,110
Discounts and allowances for commercial product sales	3,162	2,656
Deferred lease liability	1,433	257
Professional fees	620	457
Accrued interest	409	492
Sales and marketing services	147	88
Other	1,298	1,319
Current portion of milestone rights liability		1,643
Accrued expenses and other current liabilities	$ 15,904	$ 15,022

Loan Arrangement with Former _2

Loan Arrangement with Former Related Party - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Feb. 29, 2016	Dec. 31, 2019	Jun. 30, 2019	Dec. 31, 2018
Related Party Transaction [Line Items]
Common stock, shares outstanding		211,787,573		187,029,967
Remaining debt amount		$ 70,020		$ 72,089
Accrued interest due to related party		2,002		6,835
Promissory notes		70,020		72,089
The Mann Group LLC
Related Party Transaction [Line Items]
Remaining debt amount			$ 70,100	72,100
Accrued interest due to related party				$ 6,800
Promissory notes		$ 70,000
The Mann Group LLC | Loan Arrangement
Related Party Transaction [Line Items]
Trustee substantial portion disposed term	3 years
Common stock, shares outstanding		9,300,000
Additional common stock shares reserved for issuance		14,000,000
The Mann Group LLC | Loan Arrangement | Common Stock
Related Party Transaction [Line Items]
Written notice period		65 days
The Mann Group LLC | Loan Arrangement | Maximum
Related Party Transaction [Line Items]
Percentage of common stock shares outstanding		5.00%
The Mann Group LLC | Loan Arrangement | Maximum | Common Stock
Related Party Transaction [Line Items]
Percentage of beneficially own in excess		19.99%
The Mann Group LLC | Loan Arrangement | Minimum | Common Stock
Related Party Transaction [Line Items]
Percentage of beneficially own in excess		9.99%
Mr.Mann | Loan Arrangement | Common Stock
Related Party Transaction [Line Items]
Percentage of beneficial interest owned	36.00%

Borrowings - Summary of Carryin

Borrowings - Summary of Carrying Amount of Borrowings (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Mann Group promissory notes	$ 70,020	$ 72,089
Senior notes	10,028	19,099
Total debt — net carrying amount	118,899	102,486
Deerfield Credit Facility
Debt Instrument [Line Items]
Credit Facility		$ 11,298
MidCap Credit Facility
Debt Instrument [Line Items]
Credit Facility	$ 38,851

Borrowings - Schedule of Line o

Borrowings - Schedule of Line of Credit Facility Debt and Key Terms (Detail) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Amount Due	$ 120.3
Convertible Promissory Note | The Mann Group LLC
Debt Instrument [Line Items]
Amount Due	35	$ 71.5
Accrued interest paid-in-kind	$ 1	$ 6.8
Annual interest rate	7.00%	5.84%
Maturity date	Nov. 30, 2024	Jul. 31, 2021
Conversion price	$ 2.50	$ 4
Non-Convertible Promissory Note | The Mann Group LLC
Debt Instrument [Line Items]
Amount Due	$ 35.1
Accrued interest paid-in-kind	$ 1
Annual interest rate	7.00%
Maturity date	Nov. 30, 2024
June 2020 Note
Debt Instrument [Line Items]
Amount Due	$ 2.6
Maturity date	Jun. 30, 2020
5.75% 2024 Convertible Notes
Debt Instrument [Line Items]
Amount Due	$ 5	$ 18.7
Annual interest rate	5.75%	5.75%
Maturity date	Nov. 30, 2024	Oct. 31, 2021
Conversion price	$ 3	$ 5.15
December 2020 Note
Debt Instrument [Line Items]
Amount Due	$ 2.6
Maturity date	Dec. 31, 2020
MidCap Credit Facility
Debt Instrument [Line Items]
Amount Due	$ 40
Maturity date	Aug. 31, 2024
MidCap Credit Facility | LIBOR
Debt Instrument [Line Items]
Annual interest rate	6.75%
Interest rate floor	2.00%
Deerfield Credit Facility | 9.75% Credit Facility Due July 2019
Debt Instrument [Line Items]
Amount Due		$ 4
Annual interest rate		9.75%
Maturity date		Jul. 31, 2019
Deerfield Credit Facility | 9.75% Credit Facility Due August 2019
Debt Instrument [Line Items]
Amount Due		$ 5
Annual interest rate		9.75%
Maturity date		Aug. 31, 2019
Deerfield Credit Facility | 8.75% Credit Facility Due May 2019
Debt Instrument [Line Items]
Amount Due		$ 2.5
Annual interest rate		8.75%
Maturity date		May 31, 2019

Borrowings - Schedule of Maturi

Borrowings - Schedule of Maturities of Our Borrowings (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Debt Disclosure [Abstract]
2020	$ 5,262
2021	4,444
2022	13,333
2023	13,333
2024	83,940
Total principal payments	120,312
Unamortized discount	(539)
Debt issuance costs	(874)
Total debt — net carrying amount	$ 118,899	$ 102,486

Borrowings - Deerfield Facility

Borrowings - Deerfield Facility Financing Obligation - Additional Information (Detail) - USD ($)	Jul. 18, 2019	Dec. 31, 2019	Dec. 31, 2014	Dec. 31, 2014	Jun. 30, 2019	Dec. 31, 2018	Jul. 01, 2013
Debt Instrument [Line Items]
Principal amount		$ 120,300,000
Common stock, shares issued		211,787,573				187,029,967
2019 notes
Debt Instrument [Line Items]
Unamortized debt issuance costs and debt discount		$ 0				$ 200,000
Deerfield | 2019 notes
Debt Instrument [Line Items]
Principal amount							$ 160,000,000
Senior notes, effective interest rate							9.75%
Conversion of notes to common shares, value	$ 1,600,000
Debt instrument, remaining borrowing capacity		60,000,000
Repayments of aggregate principal amount	$ 2,400,000
Common stock, shares issued	1,514,423
Deerfield | Facility Financing Obligation
Debt Instrument [Line Items]
Conversion of notes to common shares, value				$ 100,000,000
Repayments of aggregate principal amount		5,000,000
Deerfield | Tranche B notes
Debt Instrument [Line Items]
Senior notes, effective interest rate			8.75%	8.75%
Debt instrument additional borrowing capacity			$ 20,000,000
Debt instrument, remaining borrowing capacity		20,000,000
Deerfield | Facility Financing Obligation
Debt Instrument [Line Items]
Principal amount					$ 9,000,000
Debt instrument, remaining borrowing capacity		$ 80,000,000

Borrowings - August 2019 Exchan

Borrowings - August 2019 Exchange Agreement - Additional Information (Detail) - USD ($) $ in Millions	Aug. 06, 2019	Dec. 31, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Common stock, shares issued		211,787,573	187,029,967
2019 Notes Tranche 1 | Deerfield
Debt Instrument [Line Items]
Repayments of aggregate principal amount	$ 2
Common stock, shares issued	2,678,571
Exchange in aggregate principal amount	$ 3

Borrowings - Facility Financing

Borrowings - Facility Financing Obligation - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Milestone rights liability	$ 7,263	$ 7,263	$ 7,201
Deerfield | Facility Financing Obligation
Debt Instrument [Line Items]
Remaining milestone rights liability	7,300	7,300	$ 8,900
Payment for milestone liability	5,000
Milestone rights liability, current	1,600	1,600
Milestone interest expense		3,400
Milestone rights liability	$ 7,300	$ 7,300

Borrowings - MidCap Credit Faci

Borrowings - MidCap Credit Facility - Additional Information (Detail)	Aug. 06, 2019USD ($)Installment$ / sharesshares	Dec. 31, 2019USD ($)	Aug. 31, 2019USD ($)	Dec. 31, 2019USD ($)
Debt Instrument [Line Items]
Unamortized debt issuance costs		$ 874,000		$ 874,000
Unamortized debt discount		539,000		539,000
MidCap Credit Facility
Debt Instrument [Line Items]
Principal amount			$ 75,000,000
Advance of borrowing		25,000,000
Amount available under credit facility			35,000,000
Unamortized debt issuance costs		800,000		800,000
Unamortized debt discount		$ 300,000		$ 300,000
Credit facility, origination fee	$ 400,000
Interest on loans increased, percentage	2.00%
Term loan advance percentage of amount drawdown	3.25%
Warrants to purchase of common stock | shares	1,171,614
Exercise price of warrants | $ / shares	$ 1.11
MidCap Credit Facility | Between First Anniversary and Prior to Second Anniversary of Closing Date
Debt Instrument [Line Items]
Early termination fees, percentage	2.00%
MidCap Credit Facility | Prior to First Anniversary of Closing Date
Debt Instrument [Line Items]
Early termination fees, percentage	3.00%
MidCap Credit Facility | After Second Anniversary and Prior to Third Anniversary of Closing Date
Debt Instrument [Line Items]
Early termination fees, percentage	1.00%
MidCap Credit Facility | LIBOR
Debt Instrument [Line Items]
Interest rate (LIBOR)				6.75%
Interest rate floor				2.00%
MidCap Credit Facility | Minimum
Debt Instrument [Line Items]
Debt Instrument Exit Fee Percentage		6.00%
MidCap Credit Facility | Maximum
Debt Instrument [Line Items]
Debt Instrument Exit Fee Percentage		7.00%
Tranche 1 | MidCap Credit Facility
Debt Instrument [Line Items]
Advance of borrowing	$ 40,000,000
Tranche 1 | MidCap Credit Facility | LIBOR
Debt Instrument [Line Items]
Interest rate (LIBOR)	6.75%
Interest rate floor	2.00%
Tranche 2 | MidCap Credit Facility
Debt Instrument [Line Items]
Amount available under credit facility			10,000,000
Debt instrument, minimum target net revenue			30,000,000
Minimum cash covenant	$ 15,000,000	$ 15,000,000		$ 15,000,000
Tranche 2 | MidCap Credit Facility | LIBOR
Debt Instrument [Line Items]
Interest rate (LIBOR)	6.75%
Interest rate floor	2.00%
Tranche 3 | MidCap Credit Facility
Debt Instrument [Line Items]
Amount available under credit facility			$ 25,000,000
Debt instrument payment term description				principal on each term loan advance under Tranche 3 is payable beginning on the later of (i) September 1, 2021, and (ii) the first day of the first full calendar month immediately following such term loan advance, in an amount equal to the outstanding term loan advance in respect of Tranche 3 divided by the number of full calendar months remaining before August 1, 2024.
Minimum cash covenant		$ 20,000,000		$ 20,000,000
Tranche 3 | MidCap Credit Facility | LIBOR
Debt Instrument [Line Items]
Interest rate (LIBOR)	6.75%
Interest rate floor	2.00%
Tranche 1 and Tranche 2 | MidCap Credit Facility
Debt Instrument [Line Items]
Debt payable number of equal monthly installments | Installment	36
Debt instrument payment term description				principal on each term loan advance under Tranche 3 is payable beginning on the later of (i) September 1, 2021, and (ii) the first day of the first full calendar month immediately following such term loan advance, in an amount equal to the outstanding term loan advance in respect of Tranche 3 divided by the number of full calendar months remaining before August 1, 2024.
Tranche 2 and 3 [Member] | MidCap Credit Facility
Debt Instrument [Line Items]
Minimum cash covenant	$ 20,000,000

Borrowings - Senior Note - Addi

Borrowings - Senior Note - Additional Information (Detail)	Aug. 06, 2019USD ($)d$ / shares	Aug. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Debt Instrument [Line Items]
Senior notes outstanding			$ 10,028,000	$ 19,099,000
Principal amount			120,300,000
Gain (loss) on extinguishment of debt	$ 3,100,000		3,529,000	(765,000)
Unamortized premium			0	400,000
Bruce & Co.,Inc.
Debt Instrument [Line Items]
Principal amount		$ 5,200,000	18,700,000
2021 Notes
Debt Instrument [Line Items]
Senior notes outstanding			$ 10,200,000	$ 18,700,000
2021 Notes | Privately Negotiated Exchange Agreement | Bruce & Co.,Inc.
Debt Instrument [Line Items]
Repayments of aggregate principal amount		$ 1,500,000
Issuance of common stock to note holders | shares		4,017,857
Exchange price per share | $ / shares		$ 1.12
2024 Convertible Notes
Debt Instrument [Line Items]
No of convertible shares	333.3333
Principal amount per share | $ / shares	$ 1,000
Conversion price of shares | $ / shares	$ 3
Debt default, description			If certain bankruptcy and insolvency-related events of default occur, the principal of, and accrued and unpaid interest on, all of the then outstanding 2024 convertible notes shall automatically become due and payable. If an event of default other than certain bankruptcy and insolvency-related events of defaults occurs and is continuing, the Trustee or the holders of at least 25% in aggregate principal amount of the then-outstanding 2024 convertible notes, by written notice to the Trustee, may declare the 2024 convertible notes due and payable at their principal amount plus any accrued and unpaid interest, and thereupon the Trustee may, at its discretion, proceed to protect and enforce the rights of the holders by the appropriate judicial proceedings. Notwithstanding the foregoing, the Indenture provides that, to the extent the Company elects, the sole remedy for an event of default relating to certain failures by the Company to comply with certain reporting covenants in the Indenture will, for the first 180 days after such event of default, consist exclusively of the right to receive additional interest on the 2024 convertible notes.
Percentage of repurchase price	100.00%
Debt Instrument, redemption description			The Company may elect at its option to cause all or any portion of the 2024 convertible notes to be mandatorily converted in whole or in part at any time prior to the close of business on the business day immediately preceding the maturity date, if the last reported sale price of its common stock equals or exceeds 120% of the conversion price then in effect for at least 10 trading days in any 20 trading day period, ending within five business days prior to the date of the mandatory conversion notice.
Percentage of conversion price equaling stock price	120.00%
Number of trading days | d	10
Consecutive trading days	20 days
2024 Convertible Notes | Bruce & Co.,Inc.
Debt Instrument [Line Items]
Principal amount		$ 5,000,000
Senior notes, effective interest rate	5.75%
Debt instrument, maturity date, description			The 2024 convertible notes will mature on the earlier of (i) November 4, 2024 or (ii) the 91st day after the payment in full of, and termination and discharge of all obligations (other than contingent indemnity obligations) under the MidCap Credit Facility.
June 2020 Note
Debt Instrument [Line Items]
Principal amount			$ 2,600,000
Maturity date			Jun. 30, 2020
June 2020 Note | Bruce & Co.,Inc.
Debt Instrument [Line Items]
Maturity date		Jun. 30, 2020
December 2020 Note
Debt Instrument [Line Items]
Principal amount			$ 2,600,000
Maturity date			Dec. 31, 2020
December 2020 Note | Bruce & Co.,Inc.
Debt Instrument [Line Items]
Maturity date		Dec. 31, 2020

Borrowings - Mann Group Promiss

Borrowings - Mann Group Promissory Notes - Additional Information (Detail)	Aug. 06, 2019USD ($)	Aug. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2018USD ($)$ / sharesshares
Debt Instrument [Line Items]
Common stock, shares issued | shares			211,787,573	187,029,967
Principal amount			$ 120,300,000
Gain (loss) on extinguishment of debt	$ 3,100,000		3,529,000	$ (765,000)
The Mann Group LLC
Debt Instrument [Line Items]
Gain (loss) on extinguishment of debt		$ 400,000
Unamortized debt issuance costs and debt discount			0	$ 600,000
The Mann Group LLC | Convertible Promissory Note
Debt Instrument [Line Items]
Repayments of debt			$ 11,000,000
Conversion price of shares | $ / shares			$ 2.50	$ 4
Principal amount			$ 35,000,000	$ 71,500,000
Accrued Paid-in-Kind Interest			$ 1,000,000	$ 6,800,000
Senior notes, effective interest rate			7.00%	5.84%
Maturity date			Nov. 30, 2024	Jul. 31, 2021
The Mann Group LLC | Non-Convertible Promissory Note
Debt Instrument [Line Items]
Principal amount			$ 35,100,000
Accrued Paid-in-Kind Interest			$ 1,000,000
Senior notes, effective interest rate			7.00%
Maturity date			Nov. 30, 2024
The Mann Group LLC | New Loan Arrangement | Convertible Promissory Note
Debt Instrument [Line Items]
Conversion price of shares | $ / shares		$ 2.50	$ 2.50
Principal amount			$ 35,000,000
Senior notes, effective interest rate		7.00%
Debt instrument payment term description			quarterly
Debt instrument, date of first required interest payment		Oct. 1, 2019
Maturity date		Nov. 3, 2024
No of convertible shares		400
Principal amount per share | $ / shares		$ 1,000
The Mann Group LLC | New Loan Arrangement | Non-Convertible Promissory Note
Debt Instrument [Line Items]
Principal amount			$ 35,100,000
Senior notes, effective interest rate		7.00%
Debt instrument payment term description			quarterly
Debt instrument, date of first required interest payment		Oct. 1, 2019
Debt instrument, maturity date, description			The Mann Group non-convertible note will mature on the earlier of (i) November 3, 2024 or (ii) the 90th day after the repayment in full, and termination and discharge of all obligations (other than contingent indemnity obligations) under the MidCap Credit Facility. Interest on the Mann Group non-convertible note will be payable in kind by adding the amount thereof to the principal amount; provided that the Company may, at its option, elect to pay any such interest on any interest payment date, if certain conditions are met, in shares of the Company’s common stock at a price per shall equal to the last reported sale price on the trading day immediately prior to the interest payment date.
The Mann Group LLC | Privately Negotiated Exchange Agreement
Debt Instrument [Line Items]
Repayments of debt		$ 3,000,000
Common stock, shares issued | shares		7,142,857
Conversion price of shares | $ / shares		$ 1.12
Conversion of notes to common shares, value		$ 71,500,000
Accrued Paid-in-Kind Interest		9,500,000
The Mann Group LLC | Privately Negotiated Exchange Agreement | New Loan Arrangement | Convertible Promissory Note
Debt Instrument [Line Items]
Principal amount		35,000,000
The Mann Group LLC | Privately Negotiated Exchange Agreement | New Loan Arrangement | Non-Convertible Promissory Note
Debt Instrument [Line Items]
Principal amount		$ 35,100,000

Borrowings - Schedule of Amorti

Borrowings - Schedule of Amortization of Premium and Accretion of Debt Issuance Costs (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Debt Disclosure [Abstract]
Amortization of debt premium	$ (1,049)	$ (339)
Amortization of debt discount	295	1,155
Accretion expense — debt issuance cost	$ (111)	$ (69)

Schedule of Revenue from Collab

Schedule of Revenue from Collaborations and Services (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from collaborations and services	$ 15,993	$ 14,595	$ 15,002	$ 17,448	$ 16,031	$ 4,469	$ 3,893	$ 3,465	$ 63,038	$ 27,859
Collaborations and services
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from collaborations and services									37,734	10,583
Collaborations and services | License Agreement | United Therapeutics Corporation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from collaborations and services									31,229	6,386
Collaborations and services | Research Agreement | United Therapeutics Corporation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from collaborations and services									6,032	3,758
Collaborations and services | Collaboration and License Agreement | Receptor
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from collaborations and services									250	341
Collaborations and services | Distribution Agreement | Cipla Ltd
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from collaborations and services									148	$ 98
Collaborations and services | Distribution Agreement | Biomm S.A.
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from collaborations and services									$ 75

Collaboration and Licensing A_3

Collaboration and Licensing Arrangements - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended								9 Months Ended	12 Months Ended
	May 31, 2018	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2018	Oct. 16, 2018	Dec. 31, 2017
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue		$ 40,847,000				$ 47,565,000					$ 40,847,000	$ 47,565,000		$ 750,000
Deferred revenue - current		32,503,000				36,885,000					32,503,000	36,885,000
Deferred revenue - long term		8,344,000				10,680,000					8,344,000	10,680,000
Revenue — collaborations and services		15,993,000	$ 14,595,000	$ 15,002,000	$ 17,448,000	$ 16,031,000	$ 4,469,000	$ 3,893,000	$ 3,465,000		63,038,000	27,859,000
Income Taxes Paid												240,000
Commercial product sales
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue — collaborations and services											25,304,000	17,276,000
Collaboration and License Agreement | Receptor
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue - current		300,000									300,000
Collaboration and License Agreement | United Therapeutics Corporation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment received													$ 45,000,000
Milestone Payment Received											12,500,000
Total transaction price		101,400,000									101,400,000
Deferred revenue		38,400,000									38,400,000
Deferred revenue - current		31,900,000									31,900,000
Deferred revenue - long term		6,500,000									6,500,000
Collaboration and License Agreement | United Therapeutics Corporation | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Potential milestone payments to be receive		25,000,000									25,000,000
Additional option exercise and development milestone payments to be receive		40,000,000									40,000,000
Research Agreement | United Therapeutics Corporation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment received							$ 10,000,000
Total transaction price		10,000,000									10,000,000
Deferred revenue - current		200,000									200,000
Research Agreement | United Therapeutics Corporation | Engineering Consulting Services
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total transaction price		1,000,000									$ 1,000,000
Revenue performance obligation, method used											The revenue for the engineering consulting services was recognized using a ratable method until the obligation was satisfied. The Company believes that this method best reflects the measure of progress toward complete satisfaction of the performance obligation.
Research Agreement | United Therapeutics Corporation | Product Prototype
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total transaction price		9,000,000									$ 9,000,000
Revenue performance obligation, method used											The revenue for the product prototype is recognized using an output method (based on project milestones achieved and surveys of performance completed to date). The Company believes that this method best reflects the measure of progress toward complete satisfaction of the performance obligation.
Research Agreement | United Therapeutics Corporation | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Potential milestone payments to be receive		30,000,000									$ 30,000,000
Supply and Distribution Agreement | Commercial product sales | Biomm
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue — collaborations and services										$ 700,000
License and Distribution Agreement | Foreign Country | India Tax Authority
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Income Taxes Paid												$ 200,000
License and Distribution Agreement | Cipla Ltd
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue		1,900,000									1,900,000
Deferred revenue - current		100,000									100,000
Deferred revenue - long term		$ 1,800,000									$ 1,800,000
Marketing and distribution agreement date	2018-05

Collaboration and Licensing A_4

Collaboration and Licensing Arrangements - Additional Information (Detail 1) - USD ($) $ in Millions	Dec. 31, 2019	May 31, 2018	Dec. 31, 2016
Collaboration and License Agreement | Receptor | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2017-01-01
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue recognition period			4 years
Deferred revenue - nonrefundable license fee			$ 1
Collaboration and License Agreement | United Therapeutics Corporation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue - nonrefundable license fee	$ 101.4
Collaboration and License Agreement | United Therapeutics Corporation | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2018-10-01
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue recognition period	39 months
License and Distribution Agreement | Cipla Ltd | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2018-06-01
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue recognition period		15 years
Deferred revenue - nonrefundable license fee		$ 2.2

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Fair Value Of Financial Instruments [Line Items]
Cash and cash equivalents	$ 29,906,000	$ 71,157,000
Restricted cash	316,000	527,000
Short-term investments	$ 19,978,000
Fair value of note payable to related party, description	The fair value measurement of debt instruments is based on a discounted cash flow model and is sensitive to the change in yield (Level 3 in the fair value hierarchy
Embedded derivatives	$ 0
Money Market Funds
Fair Value Of Financial Instruments [Line Items]
Cash and cash equivalents	29,900,000	71,200,000
Restricted cash	300,000	500,000
U.S. Treasury bills or notes.
Fair Value Of Financial Instruments [Line Items]
Short-term investments	$ 20,000,000	$ 0

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Fair Value Measurement of Debt Instruments Based on Discounted Cash Flow Model and Sensitive to Change in Yield (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Mann Group Promissory Notes | Note Payable Yield Changes 1
Fair Value Of Financial Instruments [Line Items]
Note payable, percentage of yield	31	29
Note payable, percentage of interest rate increases (decreases)	2.00%
Note payable to related party, fair value	$ 44.1	$ 46.2
Change in fair value of note payable value due to change in interest rate percentage	$ (2.1)
Increase (decrease) in fair value of note payable percentage due to increases (decreases) in interest rate percentage	(4.50%)
Mann Group Promissory Notes | Note Payable Yield Changes 2
Fair Value Of Financial Instruments [Line Items]
Note payable, percentage of yield	27	29
Note payable, percentage of interest rate increases (decreases)	(2.00%)
Note payable to related party, fair value	$ 48.5	$ 46.2
Change in fair value of note payable value due to change in interest rate percentage	$ 2.3
Increase (decrease) in fair value of note payable percentage due to increases (decreases) in interest rate percentage	5.00%
Mann Group Promissory Notes | Note Payable Yield Changes 3
Fair Value Of Financial Instruments [Line Items]
Note payable, percentage of yield	33	29
Note payable, percentage of interest rate increases (decreases)	4.00%
Note payable to related party, fair value	$ 42.2	$ 46.2
Change in fair value of note payable value due to change in interest rate percentage	$ (4)
Increase (decrease) in fair value of note payable percentage due to increases (decreases) in interest rate percentage	(8.70%)
Mann Group Promissory Notes | Note Payable Yield Changes 4
Fair Value Of Financial Instruments [Line Items]
Note payable, percentage of yield	25	29
Note payable, percentage of interest rate increases (decreases)	(4.00%)
Note payable to related party, fair value	$ 51	$ 46.2
Change in fair value of note payable value due to change in interest rate percentage	$ 4.8
Increase (decrease) in fair value of note payable percentage due to increases (decreases) in interest rate percentage	10.40%
Senior Notes | Note Payable Yield Changes 1
Fair Value Of Financial Instruments [Line Items]
Note payable, percentage of yield	31	29
Note payable, percentage of interest rate increases (decreases)	2.00%
Note payable to related party, fair value	$ 7.8	$ 8
Change in fair value of note payable value due to change in interest rate percentage	$ (0.2)
Increase (decrease) in fair value of note payable percentage due to increases (decreases) in interest rate percentage	(2.50%)
Senior Notes | Note Payable Yield Changes 2
Fair Value Of Financial Instruments [Line Items]
Note payable, percentage of yield	27	29
Note payable, percentage of interest rate increases (decreases)	(2.00%)
Note payable to related party, fair value	$ 8.2	$ 8
Change in fair value of note payable value due to change in interest rate percentage	$ 0.2
Increase (decrease) in fair value of note payable percentage due to increases (decreases) in interest rate percentage	2.50%
Senior Notes | Note Payable Yield Changes 3
Fair Value Of Financial Instruments [Line Items]
Note payable, percentage of yield	33	29
Note payable, percentage of interest rate increases (decreases)	4.00%
Note payable to related party, fair value	$ 7.6	$ 8
Change in fair value of note payable value due to change in interest rate percentage	$ (0.4)
Increase (decrease) in fair value of note payable percentage due to increases (decreases) in interest rate percentage	(5.00%)
Senior Notes | Note Payable Yield Changes 4
Fair Value Of Financial Instruments [Line Items]
Note payable, percentage of yield	25	29
Note payable, percentage of interest rate increases (decreases)	(4.00%)
Note payable to related party, fair value	$ 8.4	$ 8
Change in fair value of note payable value due to change in interest rate percentage	$ 0.4
Increase (decrease) in fair value of note payable percentage due to increases (decreases) in interest rate percentage	5.00%
MidCap Credit Facility | Note Payable Yield Changes 1
Fair Value Of Financial Instruments [Line Items]
Note payable, percentage of yield	12.5	11.5
Note payable, percentage of interest rate increases (decreases)	1.00%
Note payable to related party, fair value	$ 39	$ 40
Change in fair value of note payable value due to change in interest rate percentage	$ (1)
Increase (decrease) in fair value of note payable percentage due to increases (decreases) in interest rate percentage	(2.50%)
MidCap Credit Facility | Note Payable Yield Changes 2
Fair Value Of Financial Instruments [Line Items]
Note payable, percentage of yield	10.5	11.5
Note payable, percentage of interest rate increases (decreases)	(1.00%)
Note payable to related party, fair value	$ 41	$ 40
Change in fair value of note payable value due to change in interest rate percentage	$ 1
Increase (decrease) in fair value of note payable percentage due to increases (decreases) in interest rate percentage	2.50%
MidCap Credit Facility | Note Payable Yield Changes 3
Fair Value Of Financial Instruments [Line Items]
Note payable, percentage of yield	13.5	11.5
Note payable, percentage of interest rate increases (decreases)	2.00%
Note payable to related party, fair value	$ 38.1	$ 40
Change in fair value of note payable value due to change in interest rate percentage	$ (1.9)
Increase (decrease) in fair value of note payable percentage due to increases (decreases) in interest rate percentage	(4.80%)
MidCap Credit Facility | Note Payable Yield Changes 4
Fair Value Of Financial Instruments [Line Items]
Note payable, percentage of yield	9.5	11.5
Note payable, percentage of interest rate increases (decreases)	(2.00%)
Note payable to related party, fair value	$ 42.1	$ 40
Change in fair value of note payable value due to change in interest rate percentage	$ 2.1
Increase (decrease) in fair value of note payable percentage due to increases (decreases) in interest rate percentage	5.30%

Fair Value of Financial Instr_5

Fair Value of Financial Instruments - Fair Value of Financial Instruments (Detail) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Financial liabilities:
Financial liabilities fair value	$ 110.6	$ 102
MidCap Credit Facility
Financial liabilities:
Financial liabilities fair value	40
Deerfield Credit Facility
Financial liabilities:
Financial liabilities fair value		11.4
June 2020 Note
Financial liabilities:
Financial liabilities fair value	2.3
2024 Convertible Notes
Financial liabilities:
Financial liabilities fair value	3.7
December 2020 Note
Financial liabilities:
Financial liabilities fair value	2
Mann Group Promissory Notes
Financial liabilities:
Financial liabilities fair value	46.2	55
Milestone Rights Liability
Financial liabilities:
Financial liabilities fair value	16.4	18.1
Senior Convertible Notes
Financial liabilities:
Financial liabilities fair value		17.5
Carrying Value
Financial liabilities:
Financial liabilities fair value	126.2	111.4
Carrying Value | MidCap Credit Facility
Financial liabilities:
Financial liabilities fair value	38.9
Carrying Value | Deerfield Credit Facility
Financial liabilities:
Financial liabilities fair value		11.3
Carrying Value | June 2020 Note
Financial liabilities:
Financial liabilities fair value	2.5
Carrying Value | 2024 Convertible Notes
Financial liabilities:
Financial liabilities fair value	5
Carrying Value | December 2020 Note
Financial liabilities:
Financial liabilities fair value	2.5
Carrying Value | Mann Group Promissory Notes
Financial liabilities:
Financial liabilities fair value	70	72.1
Carrying Value | Milestone Rights Liability
Financial liabilities:
Financial liabilities fair value	7.3	8.9
Carrying Value | Senior Convertible Notes
Financial liabilities:
Financial liabilities fair value		19.1
Estimate of Fair Value Measurement | Fair Value, Inputs, Level 3
Financial liabilities:
Financial liabilities fair value	110.6	102
Estimate of Fair Value Measurement | Fair Value, Inputs, Level 3 | MidCap Credit Facility
Financial liabilities:
Financial liabilities fair value	40
Estimate of Fair Value Measurement | Fair Value, Inputs, Level 3 | Deerfield Credit Facility
Financial liabilities:
Financial liabilities fair value		11.4
Estimate of Fair Value Measurement | June 2020 Note | Fair Value, Inputs, Level 3
Financial liabilities:
Financial liabilities fair value	2.3
Estimate of Fair Value Measurement | 2024 Convertible Notes | Fair Value, Inputs, Level 3
Financial liabilities:
Financial liabilities fair value	3.7
Estimate of Fair Value Measurement | December 2020 Note | Fair Value, Inputs, Level 3
Financial liabilities:
Financial liabilities fair value	2
Estimate of Fair Value Measurement | Mann Group Promissory Notes | Fair Value, Inputs, Level 3
Financial liabilities:
Financial liabilities fair value	46.2	55
Estimate of Fair Value Measurement | Milestone Rights Liability | Fair Value, Inputs, Level 3
Financial liabilities:
Financial liabilities fair value	$ 16.4	18.1
Estimate of Fair Value Measurement | Senior Convertible Notes | Fair Value, Inputs, Level 3
Financial liabilities:
Financial liabilities fair value		$ 17.5

Common and Preferred Stock - Ad

Common and Preferred Stock - Additional Information (Detail) - USD ($)	Dec. 26, 2019	Dec. 23, 2019	Jul. 31, 2019	Dec. 31, 2018	Apr. 30, 2018	Feb. 28, 2018	Dec. 31, 2019	Dec. 31, 2018
Class of Stock [Line Items]
Common stock, shares authorized				280,000,000			280,000,000	280,000,000
Common stock, par value				$ 0.01			$ 0.01	$ 0.01
Undesignated preferred stock, shares authorized				10,000,000			10,000,000	10,000,000
Undesignated preferred stock, par value				$ 0.01			$ 0.01	$ 0.01
Common stock, shares issued				187,029,967			211,787,573	187,029,967
Common stock, shares outstanding				187,029,967			211,787,573	187,029,967
Undesignated preferred stock, shares outstanding				0			0	0
Other expense							$ (7,306,000)	$ (10,140,000)
Common Stock | Public Offering
Class of Stock [Line Items]
Number of shares sold during the period								26,667,000
Purchase Agreements
Class of Stock [Line Items]
Stock purchase agreements date					Apr. 30, 2018	Feb. 28, 2018
Purchase Agreements | Common Stock
Class of Stock [Line Items]
Amount of net proceeds from issuance of securities					$ 26,400,000
Number of shares sold during the period					14,000,000
Exchange price per share					$ 2
Purchase Agreements | Warrants
Class of Stock [Line Items]
Exercise price of warrants					$ 2.38
Warrants expiration, date					Apr. 9, 2019
Closing of Offering Date					Apr. 9, 2018
Purchase Agreements | Warrants | Maximum
Class of Stock [Line Items]
Warrants to purchase common stock					14,000,000
Contolled Equity Offering Sales Agreement | Cantor Fitzgerald | Common Stock | Maximum
Class of Stock [Line Items]
Amount of net proceeds from issuance of securities						$ 50,000,000
At Market Issuance Sales Agreement
Class of Stock [Line Items]
Amount of net proceeds from issuance of securities							$ 0	$ 400,000
Number of shares sold during the period							0	230,445
At Market Issuance Sales Agreement | Cantor Fitzgerald | Common Stock
Class of Stock [Line Items]
Amount of net proceeds from issuance of securities							$ 3,200,000	$ 2,100,000
Number of shares sold during the period							2,584,964	1,028,432
Exchange price per share				$ 2.03			$ 1.24	$ 2.03
Underwriting Agreement with Leerink Partners LLC
Class of Stock [Line Items]
Stock purchase agreements date				Dec. 31, 2018
Exercise price of warrants		$ 1.311
Warrants expiration, date		Jun. 26, 2020		Dec. 26, 2019
Warrants modified		11,750,000
Warrants exercised		4,500,000
Warrants expired unexercised	11,583,333
Remaining warrants available for purchase							7,250,000
Underwriting Agreement with Leerink Partners LLC | Minimum
Class of Stock [Line Items]
Warrants exercised		4,500,000
Underwriting Agreement with Leerink Partners LLC | Common Stock
Class of Stock [Line Items]
Amount of net proceeds from issuance of securities				$ 37,300,000
Exchange price per share				$ 1.50				1.50
Underwriting Agreement with Leerink Partners LLC | Common Stock | Public Offering
Class of Stock [Line Items]
Number of shares sold during the period				26,666,667
Underwriting Agreement with Leerink Partners LLC | Warrants
Class of Stock [Line Items]
Amount of net proceeds from issuance of securities		$ 5,900,000
Exercise price of warrants				$ 1.60			$ 1.60	$ 1.60
Closing of Offering Date							Jun. 26, 2020
Repurchase of common stock , shares			3,333,334
Repurchase of common stock , value			$ 400,000
Additional paid-in capital		$ 700,000	200,000
Other expense			$ 200,000
Underwriting Agreement with Leerink Partners LLC | Warrants | Maximum
Class of Stock [Line Items]
Warrants to purchase common stock				26,666,667				26,666,667

Components of Basic and Diluted

Components of Basic and Diluted EPS Computations (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
EPS — basic and diluted:
Net loss (numerator)	$ (14,263)	$ (10,370)	$ (12,387)	$ (14,883)	$ (9,747)	$ (24,168)	$ (22,675)	$ (30,385)	$ (51,903)	$ (86,975)
Weighted average common shares (denominator)	206,689	199,906	188,054	187,434	161,397	153,597	140,054	120,911	195,584	144,136
Net loss per share	$ (0.07)	$ (0.05)	$ (0.07)	$ (0.08)	$ (0.06)	$ (0.16)	$ (0.16)	$ (0.25)	$ (0.27)	$ (0.60)

Potential Dilutive Securities O

Potential Dilutive Securities Outstanding that are Considered Antidilutive (Detail) - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share	39,682,839	78,212,465
Exercise of Common Stock Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share	14,135,681	10,976,118
Conversion of Convertible Notes Payable to Former Related Party into Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share	14,000,000	21,909,541
Exercise of Warrants Associated with Public Offering
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share	7,250,000	26,666,667
Exercise of Warrants Associated with Midcap Credit Facility
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share	1,171,614
Conversion of Convertible Notes into Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share	1,666,667	3,629,627
Vesting of Restricted Stock Units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share	1,057,047	691,266
Employee Stock Purchase Plan
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share	369,979	307,395
Exercise of Common Stock Warrants
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share	31,851	31,851
Exercise of Warrants Associated with Direct Placement
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share		14,000,000

Stock Award Plans - Additional

Stock Award Plans - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	May 16, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	$ 6,203	$ 6,857
Weighted average grant date fair value of the stock options granted	$ 1.32	$ 1.51
Cash received from the exercise of options	$ 124
Total fair value of restricted stock units vested	1,100	$ 1,400
Total grant date fair value of restricted stock units outstanding	$ 2,300	2,400
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	10 years
Weighted average vesting period for unrecognized compensation expense	2 years 10 months 24 days
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
Weighted average vesting period for unrecognized compensation expense	1 year
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	36 months
Vesting rights percentage	25.00%
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
Restricted Stock | Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting rights percentage	25.00%
Performance-based Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation cost		$ 1,900
Unrecognized compensation expense related to options	$ 1,100
Options and Performance-based Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense related to options	9,900
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense related to non-option	$ 600
2018 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity incentive plan, shares			12,000,000

Stock Based Award Plans (Detail

Stock Based Award Plans (Detail) - shares	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Options	14,135,681	10,976,118
Outstanding Restricted Stock Units	1,057,047	691,266
Shares Available for Future Issuance	4,710,565
2004 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Options	451,149
2013 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Options	4,714,169
Outstanding Restricted Stock Units	393,309
2018 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Options	8,934,586
Outstanding Restricted Stock Units	663,738
Shares Available for Future Issuance	4,710,565
2004 Non Employee Directors Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Options	35,777

Stock Based Compensation Expens

Stock Based Compensation Expense Recognized in Accompanying Consolidated Statements of Operations by Category (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation	$ 6,203	$ 6,857
Cost of Goods Sold
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation	601	379
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation	356	1,203
Selling, General and Administrative Expenses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation	4,508	$ 5,275
Cost of Revenue — Collaborations and Services
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation	$ 738

Fair Value of Employee Stock Op

Fair Value of Employee Stock Options Assumptions (Detail)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate, minimum	1.52%	2.63%
Risk free interest rate, maximum	2.51%	3.11%
Volatility, minimum	93.05%	92.68%
Volatility, maximum	94.25%	93.62%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected lives	6 years 2 months 12 days	5 years 10 months 24 days
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected lives	9 years 4 months 13 days	7 years 2 months 8 days

Summary of Stock Options Outsta

Summary of Stock Options Outstanding (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Number of Shares
Outstanding at January 1, 2019	10,976,118
Granted	5,613,253
Exercised	(67,461)
Forfeited	(1,395,644)
Expired	(990,585)
Outstanding at December 31, 2019	14,135,681	10,976,118
Exercisable at December 31, 2019	4,554,661
Weighted Average Exercise Price per Share
Outstanding at January 1, 2019	$ 5.75
Granted	1.32
Exercised	1.10
Forfeited	2.25
Expired	17.07
Outstanding at December 31, 2019	3.09	$ 5.75
Exercisable at December 31, 2019	$ 6.20
Weighted Average Remaining Contractual Term (Years)
Outstanding	7 years 10 months 2 days	7 years 9 months 29 days
Exercisable at December 31, 2019	6 years
Aggregate Intrinsic Value
Outstanding at December 31, 2019	$ 182
Exercisable at December 31, 2019	$ 86

Summary of Restricted Stock Uni

Summary of Restricted Stock Unit Activity (Detail)	12 Months Ended
	Dec. 31, 2019$ / sharesshares
Number of Shares
Outstanding at January 1, 2019 | shares	691,266
Granted | shares	1,293,690
Vested | shares	(804,105)
Forfeited | shares	(123,804)
Outstanding at December 31, 2019 | shares	1,057,047
Weighted Average Grant Date Fair Value per Share
Outstanding at January 1, 2019 | $ / shares	$ 3.72
Granted | $ / shares	1.42
Vested | $ / shares	2.33
Forfeited | $ / shares	2.06
Outstanding at December 31, 2019 | $ / shares	$ 2.16

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)

Dec. 26, 2019shares

Dec. 23, 2019$ / sharesshares

Aug. 02, 2019

Nov. 29, 2017USD ($)

May 05, 2017USD ($)

Jul. 31, 2019shares

Dec. 31, 2018$ / sharesshares

Jun. 30, 2018USD ($)Vehicle

Dec. 31, 2019USD ($)Vehicle$ / sharesshares

Dec. 31, 2018USD ($)$ / sharesshares

Aug. 06, 2019$ / sharesshares

Jan. 01, 2019USD ($)

Jul. 01, 2013USD ($)

Commitments And Contingencies [Line Items]

Purchase obligation extended term

2026

Supply Agreement expiration period

Dec. 31, 2026

Supply Agreement renewal period

2 years

Foreign currency hedging transactions period

90 days

Operating lease costs

$ 1,500,000

Operating lease, cash paid

1,800,000

Variable lease costs

$ 400,000

Operating lease, weighted average discount rate

7.50%

Operating lease, weighted-average remaining lease term

3 years

Underwriting Agreement with Leerink Partners LLC

Commitments And Contingencies [Line Items]

Exercise price of warrants | $ / shares

$ 1.311

Stock purchase agreements date

Dec. 31, 2018

Warrants modified | shares

11,750,000

Warrants exercised | shares

4,500,000

Warrants expired unexercised | shares

11,583,333

Warrants exercisable | shares

7,250,000

Underwriting Agreement with Leerink Partners LLC | Warrants

Commitments And Contingencies [Line Items]

Exercise price of warrants | $ / shares

$ 1.60

$ 1.60

$ 1.60

Repurchase of common stock , shares | shares

3,333,334

Lease Agreement with Enterprise | Vehicle Leases

Commitments And Contingencies [Line Items]

Number of vehicle leases | Vehicle

119

90

Operating lease rent expenses

$ 83,000

$ 65,000

Number of vehicle leases removed | Vehicle

29

Gain or loss recorded for leases removed

$ 0

Lease expiration period

48 months

Reduction in operating lease right-of-use assets

400,000

Reduction in operating lease liabilities

400,000

Operating lease right-of-use assets

$ 1,600,000

Operating lease liabilities

1,300,000

1,900,000

Operating lease, current assets

1,600,000

Operating lease, other current liabilities

600,000

Cost of Goods Sold

Commitments And Contingencies [Line Items]

Payment of long term purchase commitment, amendment fees

2,800,000

$ 2,000,000

Maximum | Underwriting Agreement with Leerink Partners LLC | Warrants

Commitments And Contingencies [Line Items]

Warrants to purchase common stock | shares

26,666,667

26,666,667

Minimum | Underwriting Agreement with Leerink Partners LLC

Commitments And Contingencies [Line Items]

Warrants exercised | shares

4,500,000

MidCap Credit Facility

Commitments And Contingencies [Line Items]

Exercise price of warrants | $ / shares

$ 1.11

Warrants to purchase of common stock | shares

1,171,614

Deerfield | Milestone Rights Liability

Commitments And Contingencies [Line Items]

Contingent liability remain payable

70,000,000

Deerfield | Milestone Rights Liability | Maximum

Commitments And Contingencies [Line Items]

Contingent liability for milestone payments

$ 90,000,000

Russell Ranch Road II LLC | Office Lease

Commitments And Contingencies [Line Items]

Operating lease rent expenses

$ 35,969

$ 40,951

Operating lease right-of-use assets

3,200,000

Operating lease liabilities

2,600,000

$ 3,500,000

Operating lease, other current liabilities

$ 900,000

Percentage of annual increase in lease payment

3.00%

3.00%

Lease expiration date

Jan. 31, 2023

Jan. 31, 2023

Lease renewal option

5 years

5 years

Reimbursement amount received for tenant improvements

$ 56,325

Operating lease rent expenses

$ 500,000

Annual Purchase Requirements un

Annual Purchase Requirements under Amended Contract (Detail) € in Millions	Aug. 31, 2019EUR (€)
Purchase Obligation Fiscal Year Maturity [Abstract]
2020	€ 6.6
2021	6.6
2022	8.5
2023	10.8
2024	14.6
2025	15.5
2026	€ 19.4

Schedule of Future Minimum Offi

Schedule of Future Minimum Office And Vehicle Lease Payments (Detail) - office and vehicle - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Commitments And Contingencies [Line Items]
2020	$ 1,470,217
2021	1,499,484
2022	1,241,089
2023	87,957
Total	$ 4,298,747
2019		$ 1,595,421
2020		1,623,835
2021		1,653,101
2022		1,305,096
2023		87,957
Total		$ 6,265,410

Employee Benefit Plans - Additi

Employee Benefit Plans - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Compensation And Retirement Disclosure [Abstract]
Employer contribution savings retirement plan	$ 1.5	$ 1

Loss from Continuing Operations

Loss from Continuing Operations Before Provision for Income Tax (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
United States	$ (51,044)	$ (84,207)
Foreign	(859)	(2,528)
Loss before income tax expense	$ (51,903)	$ (86,735)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	1 Months Ended	12 Months Ended
	Aug. 31, 2004	Dec. 31, 2019	Dec. 31, 2018
Income Taxes [Line Items]
Provision for income taxes		$ 0	$ 240,000
Valuation allowance of deferred tax asset		670,617,000	665,365,000
Change in the valuation allowance		5,252,000	11,067,000
Federal operating loss carryforwards		2,100,000,000
State operating loss carryforwards		1,300,000,000
Federal operation loss carryforwards, not subject to expiration		$ 117,800,000
Operating loss carryforwards, limitations on use		Pursuant to Internal Revenue Code (“IRC”) Sections 382 and 383, annual use of the Company’s federal and state net operating loss and research and development credit carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period.
Net operating loss carryforwards	$ 216,000,000
Net operating loss and credit carryforwards, annual use limitation	$ 13,000,000
Research and development credits		$ 80,488,000	81,583,000
Research and development credits begin to expire		2020
Undistributed earnings from its foreign subsidiaries		$ 0
Adjustment of deferred tax liability due to adoption of new leases guidance		958,000
Adjustment of deferred tax asset due to adoption of new leases guidance		671,575,000	$ 665,365,000
(“ASC”) Topic 842 – Leases
Income Taxes [Line Items]
Adjustment of deferred tax liability due to adoption of new leases guidance		700,000
Adjustment of deferred tax asset due to adoption of new leases guidance		700,000
Federal
Income Taxes [Line Items]
Research and development credits		$ 54,200,000
Research and development credits begin to expire		2024
New Jersey
Income Taxes [Line Items]
Research and development credits begin to expire		2020
Connecticut
Income Taxes [Line Items]
Research and development credits		$ 900,000
Research and development credits not expire		15,700,000
State
Income Taxes [Line Items]
Research and development credits		$ 26,300,000

Provision for Income Taxes (Det

Provision for Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Current
Non-U.S.		$ 240
Total current		240
Deferred
U.S. federal	$ (8,551)	(9,164)
U.S. state	3,299	(1,903)
Total deferred	(5,252)	(11,067)
Valuation allowance	5,252	11,067
Total	$ 0	$ 240

Components of Net Deferred Tax

Components of Net Deferred Tax Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Deferred tax assets:
Net operating loss carryforwards	$ 531,970	$ 524,377
Research and development credits	80,488	81,583
Capitalized research	44	557
Milestone Rights	1,528	3,521
Accrued expenses	1,951	1,156
Loss on purchase commitment	22,167	23,194
Non-qualified stock option expense	3,128	2,551
Capitalized patent costs	4,964	5,090
Other	147	669
Lease liability	827
Interest expense limitation	1,167
Depreciation	21,132	22,560
Deferred Product Revenue & Costs	2,062	107
Total net deferred tax assets	671,575	665,365
Valuation allowance	(670,617)	$ (665,365)
Net deferred tax assets	958
Deferred tax liabilities:
Right of use asset	(751)
Other prepaids	(207)
Total deferred tax liabilities	$ (958)

Effective Income Tax Rate (Deta

Effective Income Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Federal tax benefit rate	21.00%	21.00%
Permanent items	(3.30%)	1.00%
Tax law changes	(2.70%)	(0.70%)
Stock based compensation	(0.90%)	(6.50%)
Tax attribute expirations	(4.00%)	(1.60%)
Foreign withholding tax		(0.30%)
Valuation allowance	(10.10%)	(13.20%)
Effective income tax rate	0.00%	(0.30%)

Selected Quarterly Financial _3

Selected Quarterly Financial Data (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Quarterly Financial Information Disclosure [Abstract]
Net revenues	$ 15,993	$ 14,595	$ 15,002	$ 17,448	$ 16,031	$ 4,469	$ 3,893	$ 3,465	$ 63,038	$ 27,859
Net loss	$ (14,263)	$ (10,370)	$ (12,387)	$ (14,883)	$ (9,747)	$ (24,168)	$ (22,675)	$ (30,385)	$ (51,903)	$ (86,975)
Net loss per share — basic and diluted	$ (0.07)	$ (0.05)	$ (0.07)	$ (0.08)	$ (0.06)	$ (0.16)	$ (0.16)	$ (0.25)	$ (0.27)	$ (0.60)
Weighted average common shares used to compute net loss per share — basic and diluted	206,689	199,906	188,054	187,434	161,397	153,597	140,054	120,911	195,584	144,136